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ABSTRACT 
The design of compounds that form cytotoxic, non-mutagenic 3-methyladenine adducts 
in pancreatic ß-cells is being studied in this project for potential applications in the treatment of 
diseases such as diabetes and cancer.  These compounds are composed of three components:  1) 
a cell-targeting moiety, glucosamine, which targets the insulin producing pancreatic β-cells by 
way of the GLUT-2 transporters present on these cells 2) a site-specific DNA methylating agent, 
Me-Lex, which has been shown to selectively produce cytotoxic, non-mutagenic N3-
methyladenine adducts 3) a linker component that connects the two other components together. 
The linker is a critical component because it has to be such that the cell-targeting and DNA-
methylating properties of the two functional components are maintained.  A synthetic route was 
explored, which enables the easy introduction of various linkers into the molecules.  Fluorescent 
compounds were also designed to bind weakly to DNA at the same positions as the DNA-
methylating compounds.  These fluorescent compounds will be used to calculate the binding 
constants of weakly binding compounds that bind to the minor groove of DNA at A/T rich 
regions.  The design features and the synthesis of these compounds are described. 
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 Many Americans suffer from diabetes (about 18 million) of which about 5-10 % (about 5 
million) have type-1 diabetes.1  Diabetes is a disease in which the body does not properly use, or 
does not produce, insulin.1  Insulin is a hormone secreted in the pancreas that enables cells in the 
body to take up glucose from the blood and create energy for everyday needs.  The cells that 
produce insulin in the body are pancreatic β-cells.  Type-1 diabetes results when insulin 
producing pancreatic β-cells are destroyed.  Destruction of these cells is thought to occur because 
of an immune response caused by genetic factors, viral infections, or environmental factors, but 
the mechanism of destruction is still poorly understood.2-3 
 One of the commonly used animal models to study type-1 diabetes is one in which a 
DNA damaging drug, streptozotocin (STZ), is used to kill pancreatic β-cells.  This compound, 
STZ, causes diabetes by two different mechanisms.  In one mechanism a single large dose of 
STZ is used, that causes rapid and complete destruction of pancreatic β-cells resulting in 
diabetes.4 This is a non-immune mechanism induced diabetes and is not reflective of human 
type-1 diabetes.  In the second mechanism, multiple small doses of STZ is used, which results in 
an initial drop in insulin production, followed by an immune response and causes complete 
destruction of pancreatic β-cells.4 This second mechanism, involving an immune reaction is more 
reflective of human type-1 diabetes. 
 STZ is a compound that damages (methylates) DNA at multiple sites.  However, there is 
evidence in literature to show that the particular damage, caused by STZ, that is responsible for 
the immune response in pancreatic β-cells is the formation of the 3-methyladinine (3-MeA) DNA 
adduct.4 It is difficult to study the direct correlation between the 3-MeA formation and the 
induction of the immune response resulting in diabetes in the animal models because STZ 
damages DNA at multiple sites.  In fact, damage caused by STZ at some sites on DNA (other 
 3
than N3-adenine) is believed to cause mutations and lead to the formation of tumors.  Thus, the 
damage at multiple sites and the consequent formation of tumors has complicated the study of 
type-1 diabetes using the STZ rodent model. 
 It would be possible to study the role of 3-MeA in triggering an immune response if one 
could generate exclusively 3-MeA in pancreatic β-cells.  Understanding the factors that trigger 
the immune response in pancreatic β-cells would provide and invaluable tool for the study of 
type-1 diabetes.  Furthermore, by understanding how to induce an immune response in a 
particular kind of cell by forming only 3-MeA DNA adducts in those cells can lead to the 
development of new drugs to target tumor cells, and destroy them by using the bodys immune 
system. 
 The goal of this project was to design and synthesize compounds to produce 3-MeA 
DNA adducts in insulin producing pancreatic β-cells.  The project involved combining an agent 
capable of causing exclusively one kind of damage on DNA (i.e. 3-MeA adduct) with a unit that 
can target this DNA-damaging agent preferentially to pancreatic β-cells.  This thesis describes 
the design and progress towards the synthesis of such molecules.  
CHAPTER 2. BACKGROUND AND SIGFIFICANCE 
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2.1. Background 
The goal of this project is to make compounds that can cause a specific kind of damage 
on DNA (i.e. 3-MeA adducts), which is believed to be the cause of the immune response that is 
responsible for the destruction of cells, and that can target pancreatic β-cells.  Such compounds 
would enable the investigation of the biological consequences of forming 3-MeA adducts in 
these insulin producing cells.  In order to design these new compounds that can produce 
exclusively 3-MeA adducts on DNA, one must first have a good understanding of the structure 
of DNA.  
2.1.1. DNA Structure and Damage 
B-DNA (deoxyribose nucleic acid) is in the shape of a double helix (Figure 2.1) with 
each strand of the double helix being composed of a negatively charged phosphate sugar 
backbone.  Connected to the sugars perpendicular to the double helix are the DNA bases adenine 
(A), thymine (T), guanine (G), and cytosine (C).  Hydrogen bonding between base pairs draws 
together the two phosphate sugar strands to form the double helix.  The base pairing is very 
specific with adenine always paired to thymine and guanine always paired to cytosine.  As a 
result of this base pairing that brings the two strands together to form the double helix, two 
grooves are created.  One groove is broad and is called the major groove.  Sites within the major 
groove are easier to access and most proteins that interact with DNA do so in the major groove.  
The other groove is narrow and deep and is called the minor groove.  Sites within this groove are 
more difficult to access.   
 As a result of the base pairing arrangement, certain sites on the DNA base pairs 
are exposed in the major groove, others are exposed in the minor groove, while  
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Figure 2.1.  Structure of DNA showing the major and minor groove. 
phosphate 
backbone 
base pairs 
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some sites are involved in the hydrogen bonding that draws the two DNA strands together, as 
can be seen from Figure 2.2.  Many of these sites are targets for DNA methylation by DNA-
methylating agents.  For example some of the sites in the G/C base pairs which lie in the major 
groove and can be methylated are the N7 site of guanine, the O6 site of guanine, and the 
exocyclic amine at the four position of cytosine.  In fact the highly accessible and most 
nucleophilic N7 site of guanine is one of the most commonly methylated sites on DNA.  The 
G/C base pair sites in the minor groove that can get methylated are N3 site of guanine and the 
exocyclic amine at the two position of guanine.  Similarly, in the A/T base pairs, the sites in the 
major groove that can be methylated are the N7 site of adenine, the exocyclic amine at the six 
position of adenine, and O4 site of thymine, and the sites which can be methylated in the minor 
groove are the N3 site of adenine and the O2 site of thymine.  In addition to the sites on the base 
pairs that can be methylated there are also sites on the phosphate backbone that can get 
methylated.  The N3-adenine site, which is the target for methylation in this project, is indicated 
by the bold arrow in Figure 2.2.   
Methylation on DNA can lead to different consequences depending on the site that is 
methylated.  For example, the most common methylation seen on DNA, at the N7-guanine site is 
believed to be one which has little or no biological consequences.5-8  On the other hand, 
methylation at the O6 site of guanine is known to lead to both mutations and cell toxicity.2-9 
Similarly, there is evidence to show that methylation at N3-A results in cytotoxicity but does not 
lead to mutations.5, 6, 9-12 Therefore, this 3-MeA adduct is a good choice when the goal is to kill a 
cell without causing other complications. 
 
 8
O
O
P-O
O
O
O
P
O
N
N
N
N
O
N
H
H
H N
N
N
O
H
H
O
O
O
G C
Guanine
Cytosine
major groove
1
23
4
5
6
7
8
9 1
2
3
4
5
6
minor groove
N
N
N
N N
H
H
O
O
CH3
HN
N
O
O
O
O
O
A T
Adenine
Thymine
minor groove
major groove
Alkylation Site:
O
 
Figure 2.2. DNA base pairing, major and minor groove sites and sites that can be     methylated 
on DNA.  Each arrow indicates a site on DNA which can be       alkylated. 
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  2.1.2. STZ and its Properties 
 STZ, the compound that was used to induce diabetes by the destruction of pancreatic β-
cells in animal models, is a methylating agent.  It is an α-D-glucopyranose derivative of N-
methyl-N-nitrosourea (Figure 2.3) that targets the pancreatic β-cells.  STZ is believed to target 
pancreatic β-cells due to the selective uptake of the glucose moiety by the low affinity glucose 
transporter, GLUT-2, that is present on the surface of the pancreatic β-cells.13-16  
 The DNA methylation pattern by STZ is complex.  It is known to methylate DNA at 
multiple sites such as N7-guanine, O6-guanine, N7-adenine, and N3-adenine.17 Of these adducts, 
the major adduct (70 %) which is formed by STZ is the N7-methylguanine.17 N7-methylguanine, 
as discussed above is believed to be a benign adduct.5-8 STZ also forms the O6-methylguanine 
adduct that is known to lead to mutations and cause cell toxicity because it can miscode for 
thymine during DNA replication.6-9  It is believed that this adduct is responsible for the 
formation of tumors in rodents treated with STZ, and this can lead to complications when 
studying diabetes using the STZ model. The small proportion of 3-MeA formed by STZ is 
believed to be responsible for the induction of the immune response caused by STZ in the STZ-
rodent model.  Since only a small percentage of the adducts formed by STZ cause the desired 
cell-toxicity, and since STZ treatment also induces tumor formation, it is not a very good choice 
for the study of type-1 diabetes. 
 The proof that the 3-MeA adduct was the adduct that was responsible for the immune 
response in the STZ-rodent model of type-1 diabetes came from studies with transgenic animals 
which were incapable of repairing 3-MeA adducts.4  When these  
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Figure 2.3.  Structure of Streptozotocin (STZ). 
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animals were treated with low levels of STZ there was an initial drop in insulin levels, which 
soon recovered to normal levels.  However, after a certain period of time these animals 
developed diabetes because of an immune response that destroyed the pancreatic β-cells.4  When 
compared to wild type animals that did not develop diabetes when subjected to the same 
treatment, the only thing different between these transgenic animals and wild type animals was 
the inability of the transgenic animals to repair the 3-MeA adducts.4  All other adducts formed by 
the low level treatment with STZ would have been repaired by the repair enzymes.  This shows 
that, of the various DNA adducts formed by STZ, the 3-MeA adduct, when formed in low 
quantities and is unrepaired, is probably responsible for the immune response.  This hypothesis 
that low levels of 3-MeA in pancreatic β-cells can trigger an immune response against those cells 
can be directly tested only if the 3-MeA adduct can be formed exclusively in those cells.  This 
cannot be achieved by using reagents such as STZ, which form many different DNA adducts.  
Therefore, designing new compounds that can form exclusively 3-MeA adducts in pancreatic β-
cells, would enable the investigation of the role of the 3-MeA adduct in causing the immune 
response and the factors that control the immune response. 
 2.1.3. 3-MeA Formation by Me-lex 
 Me-lex (Figure 2.4), a compound described in literature,18 is known to selectively form 3-
MeA adducts (> 95 %).  Me-lex is a neutral DNA minor groove binding compound that is an N-
methylpyrrolecarboxamide dipeptide (lex) with a methylating O-methyl sulfonate ester 
functionality attached at one end.18 Me-lex targets specifically the minor groove at A/T rich 
regions on DNA and exclusively forms 3-MeA adducts in those A/T rich regions.18 The reason it 
is exclusive to the minor groove in A/T  
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Figure 2.4.  Structure of methylating lexitropsin (Me-Lex). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13
rich regions is because of its unique binding interactions with the DNA in those regions as 
illustrated in Figure 2.5.  The interactions it has with DNA in A/T rich regions include H-bonds 
formed between the amide hydrogens of the pyrrole and the N3 of adenine and the exocyclic 
oxygen at the two position of thymine, and van der Waals interactions between the pyrrole 
hydrogens and the C2-position of adenine.18 Once Me-lex binds in the minor groove, the methyl 
group is transferred to the most nucleophilic site in the minor groove at A/T rich regions, the N3-
adenine by a concerted process to give the 3-MeA adduct.  The compound then becomes a 
negatively charged sulfonate and is repelled away from the negatively charged DNA backbone 
and will have no other biological consequence of its own.  Figure 2.6 shows a molecular model 
of Me-lex bound within the minor groove of DNA at A/T rich regions   
 The 3-MeA adducts that are formed in cells by Me-lex have been shown to be cytotoxic 
and non-mutagenic.  These adducts are processed by the base excision repair pathway that 
triggers poly(ADP)-ribose polymerase (PARP-1) activation.6  Over activation of PARP-1 due to 
high levels of 3-MeA depletes the cellular ATP levels and causes cell death by necrosis.  If the 
PARP-1 is inhibited, or base excision repair is absent, then the cell dies by apoptosis.6  It is 
believed that both these mechanisms of cell death, necrosis and apoptosis, are required for 
triggering an immune response. 
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Figure 2.5. a) Interaction of Me-Lex at A-T rich regions of DNA, in the minor groove.  
                  b) H-bonding and van der Waals interactions between adenines and the   pyrrole 
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Figure 2.6. Molecular model showing Me-lex bound with the minor groove of DNA at A/T rich 
regions.  This model was obtained by modification of a crystal structure of a similar 
compound bound to a DNA dodecamer. 
  
 
 
 
 
 
 
 16
 2.2. Significance 
This project describes the attempted design and preparation of new compounds that 
combine the pancreatic β-cell targeting ability of STZ with the selective N3-adenine methylating 
ability of Me-lex.  The ability to successfully target and generate only 3-MeA adducts in 
pancreatic β-cells, and inducing diabetes in rodent models using these new molecules, would be 
very helpful in the research of type-1 diabetes.  Also the low mutagenicity of 3-MeA, produced 
by these compounds would eliminate complications due to tumor formation that is reported for 
STZ rodent models of type-1 diabetes.17 
 If these compounds are successful in inducing an immune response against pancreatic β-
cells on can investigate the factors needed to induce an immune response against particular cells.  
This could lead to the development of a strategy to use the immune system itself to target and 
destroy tumor cells. 
CHAPTER 3. DESIGN AND SYNTHESIS OF DNA METHYLATING COMPOUNDS 
TARGETING PANCREATIC β-CELLS 
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3.1. Design of Molecules 
 The goal of this project is to make new molecules in order to deliver a sequence selective 
DNA methylating agent, namely one that can exclusively form 3-MeA DNA adducts, selectively 
to insulin producing pancreatic β-cells, by incorporating both cell targeting and DNA damaging 
properties in a single molecule.  Pancreatic β-cells can be targeted by glucose units which are 
selectively taken up by the GLUT-2 glucose transporters that are known to be present on these 
cells.  Exclusive DNA methylation at N3 of adenines can be achieved by using a compound 
described in literature, called Me-lex, which is capable of selectively producing 3-MeA adducts 
at A/T rich regions in the minor groove on DNA. Therefore, the strategy to make these new 
compounds capable of forming 3-MeA adducts in pancreatic β-cells is to incorporate, the 
selective DNA methylating ability of Me-lex with the pancreatic β-cell targeting ability of 
glucose.  This strategy is schematically depicted in Figure 3.1. 
 The design of the new compounds has three important components:  
1) a pancreatic β-cell targeting component which is the same as in STZ (see Figure 2.3), 
namely the glucose unit,  
2) a component that can selectively produce 3-MeA, similar to Me-lex, which will 
replace the N-methylnitrosourea group of STZ, and 
3) a variable linker component that will be used to attach the above two functional 
components together.   
Molecules designed in this manner should be able to specifically target pancreatic β-cells, similar 
to STZ, and exclusively produce 3-MeA adducts in those cells, unlike STZ which produces 
multiple DNA adducts.   
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Figure 3.1. Design of compounds that can generate 3-MeA in pancreatic β-cells. 
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 For compounds designed as shown in Figure 3.1 to achieve the desired goals successfully 
several factors need to be taken into account.  One important consideration is whether the 
glucose unit, which is known to target the pancreatic β-cells when the N-methylnitrosourea or 
other small units are attached to it, will be able to target pancreatic β-cells when the methylating 
Me-lex unit is attached to it. The second important factor is whether the Me-lex unit (which is 
known to produce exclusive 3-MeA adducts) will be able to still selectively target sites on DNA 
and produce exclusively 3-MeA adducts efficiently, similar to the parent Me-lex molecule, even 
when the glucose unit is tethered to it.  Therefore, the linker, which is used to connect the Me-lex 
unit to the glucose unit, assumes a critical role.  This linker, which is the only variable 
component in the design, has to be modified in order to achieve the optimum cell-targeting and 
DNA-damaging properties that are desired.  The composition of the linker can also be varied in 
order to improve the water solubility of the compounds which is required for biological 
applications. 
 The pancreatic β-cell targeting ability of the glucosamine unit with modifications at the 
nitrogen is well described in literature.19-24 Several molecules such as those shown in Figure 3.2, 
with small units attached to the N of the glucosamine have been successfully targeted to cells 
with GLUT-2 glucose transporters.19-24 However, there is not much evidence in literature of large 
units being attached to glucose units and being targeted to pancreatic β-cells.  But, there is no 
evidence that indicates that such molecules, with large components attached to glucosamine 
cannot be targeted to pancreatic β-cells.  A recent patent describes the use of a porphyrin-glucose 
conjugate (Figure 3.3) in selective photodynamic therapy for cancer.25  Increased uptake of this  
 21
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Figure 3.3. Structure of Pyro-2DG, where a large porphyrin ring is attached to a glucose 
                          unit.
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molecule by certain cancer cell lines has been described.  This increased uptake is attributed to 
the over expression of glucose transporters in these cancer cells,25 though the actual glucose 
transporters that were used to transport this molecule into cells were not identified.  If the large 
porphyrin unit is delivered within a cell by glucose transporters (possibly the GLUT-2 
transporter), then it should be possible to deliver the Me-lex unit to pancreatic β-cells via the 
GLUT-2 transporter by tethering it to glucosamine. 
 The ability of the Me-lex unit to efficiently produce exclusively 3-MeA adducts on DNA, 
despite its attachment to the glucose unit via a tether, is crucial for the success of this project.  
The glucose unit is attached at the C-terminus of the Me-lex unit, and away from the reactive 
methylating group.  It is not clear what effect the attached glucose unit will have on the 
methylating ability of the molecules.  The selective binding of the new molecules to the desired 
A/T rich sites in the minor groove of DNA is critical.  If the attached glucose unit also slides into 
the minor groove and forms favorable hydrogen bonding interactions within the groove, the 
binding affinity for these molecules will improve over the parent Me-lex molecule, and efficient 
methylation should be observed.  If on the other hand, the glucose unit has steric conflicts with 
the DNA backbone and interferes with the binding of the Me-lex unit at the A/T rich regions of 
the minor groove, then the linker will have to be of sufficient length in order to suspend the 
glucose unit outside the DNA while allowing the Me-lex unit to still bind in the target site. 
 The methylation of DNA by these molecules is a bimolecular reaction.  Therefore, 
strength of the binding of the molecules at the target site can be expected to directly affect the 
ability of these molecules to methylate the N3-A.  These compounds are designed to be weakly 
binding so that once the methyl group is transferred to the DNA, the resulting negative charge on 
the molecule will cause it to be repelled from the negatively charged phosphate backbone, and be 
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eliminated from the DNA.  However, a significant reduction in binding as compared to the 
parent Me-lex molecule, due to the attachment of the glucose unit, may compromise the 
methylating ability of the new molecules.  If such is the case, a positively charged tetraalkyl 
ammonium group can be introduced into the linker in order to increase the binding affinity.  On 
the other hand, the glucose unit may enhance the DNA binding due to favorable hydrogen 
bonding interactions within the groove, in which case one can expect efficient N3-A methylation.  
Computational methods are being employed in the laboratory to evaluate the binding of these 
new molecules at the desired target site.  Furthermore, this thesis also describes the synthesis of 
new fluorescent probes designed to measure the binding of the new compounds and 
intermediates containing the tethered glucose unit to the desired target site. 
 Based on the design considerations and the factors described above, the molecules that 
were selected for synthesis in this particular project are shown in Figure 3.4.  These two 
molecules, 1 and 2, vary in the length of the tether by one CH2 unit.  These molecules will be 
used to investigate the effect of tethering a glucose unit to the DNA methylating Me-lex 
component on the ability of these molecules to methylate the DNA.  Once the ability of these 
molecules to successfully methylate DNA is determined, these molecules can then be used in 
future studies to investigate their ability to target pancreatic β-cells via the GLUT-2 glucose 
transporter.    
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 3.2. Design of Synthetic Methodology 
 Compounds 1 and 2 were designed to test the effect of the variation in the length of the 
tether between the cell targeting glucose unit and the DNA methylating Me-lex unit by one CH2 
unit. It is expected that several variations of the linker would have to be tested before eventually 
identifying the optimum linker composition that provides favorable cell-targeting and DNA-
methylating properties.  Therefore, it is desirable to develop a synthetic methodology that allows 
for the easy introduction of modifications in the linker composition. 
 Two different approaches were taken for the synthesis of molecules 1 and 2.  The first 
approach was one that was similar to published procedures for similar compounds and would 
enable rapid completion of the target molecules.  In this synthetic approach the linker is 
introduced very early in the overall synthesis.  The second synthetic approach that was explored 
was one which would enable the introduction of variations in the linker at a late stage in the 
overall synthesis.  This approach would facilitate the efficient preparation of several molecules 
bearing different linkers. 
 The first synthetic scheme that was adopted to make compounds 1 and 2 is outlined in 
Scheme 3.1.  In this approach, the desired linker was added to the appropriate pyrrole unit, 4, in 
the second step itself to yield compounds 5 and 6.  The second pyrrole unit was then added to 
compounds 5 and 6 followed by the hydrolysis of the ester on the linker to give 14 and 15.  
These compounds can then be attached to the cell targeting glucose unit before the introduction 
of the reactive methyl sulfonate to form the final target molecules.  The reactions outlined in 
Scheme 3.1 are similar to the ones followed for the synthesis of Me-lex as described in 
literature.10 One disadvantage of this method  
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Scheme 3.1 
is that the linker is added very early in the synthetic scheme.  Therefore, every time a molecule 
with a new linker is required, the synthesis would have to be started all over right from beginning.    
 In order to be able to introduce different linkers into the molecules in a time efficient 
manor, an attempt to develop an alternative scheme in which the DNA sequence recognizing unit 
and the cell targeting unit would be made separately, and then assembled together at a late stage 
in the overall synthesis, with various linkers.  After the assembly with the appropriate linker; the 
reactive methyl sulfonate group can be introduced in the final stages of the synthesis.  A 
schematic diagram outlining this approach is shown in Figure 3.5.  The DNA sequence 
recognizing unit would terminate as a carboxylic acid, linkers would be obtained as amino-esters, 
and the cell targeting unit would be obtained in the form of an amine.  First, the DNA 
recognizing portion, as the carboxylic acid, 
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Figure 3.5. Outline of the design of the synthetic route to introduce linkers at a late stage           
in the synthesis. 
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would be condensed with the linker amine to form a new amide bond.  At the other end of the 
linker, the ester would be hydrolyzed to the carboxylic acid and condensed with the amine on the 
cell targeting unit to form another amide bond.  The final product containing the methyl 
sulfonate can then be obtained in a few steps.  
 Based on this synthetic design shown in Figure 3.5, the new overall synthetic scheme that 
was attempted is outlined in Scheme 3.2.  Starting from the same nitro  
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compound, 4, as in Scheme 3.1, the second pyrrole unit is attached to form the dipyrrole 
compound 9.  The reduction of the nitro to an amino, followed by condensation with acryloyl 
chloride gives the olefin, 10.  The ester at the other end can then be hydrolyzed to 11 and the 
different linkers can then be attached at this late stage in the overall synthesis to obtain 
compounds 23 and 24.     
 The cell-targeting glucose unit in the form of glucosamine can be attached to carboxylic 
acids which can be obtained by the hydrolysis of 23 and 24.  However, before this attachment 
reaction, the OH groups had to be protected.  The protection of the OH groups on glucosamine, 
while maintaining a free amine was achieved by following procedures described in literature26 as 
shown in Scheme 3.3.  The amine of the glucosamine is first with masked with 4-
methoxybenzaldehyde to give 16.  The OH groups of 16 are then protected with by reaction with 
acetic anhydride to give 17.  Finally the amine is and the amine is isolated and stored as the 
hydrochloride salt, 18.  
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Scheme 3.3 
 When the protected glucosamine is attached to the linker, both the cell-targeting and the 
DNA sequence recognizing components are now present in the same molecule (21 and 22).  The 
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OH groups on the glucose unit can then be deprotected and the DNA-methylating methyl 
sulfonate group can be introduced in a few steps to form the desired target molecules as shown in 
Scheme 3.4.  The reactive methyl sulfonate has to be introduced in the least step after the 
deprotection of the glucose unit in order to minimize manipulations of the compound after 
introduction of the reactive methyl group.  The glucose OH groups are not reactive to the 
methylating agent under the reaction conditions used to form the methyl sulfonate.  
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3.3. Synthesis of the DNA-Recognizing Dipyrrole Component Following Scheme 3.1 
 The synthesis of the DNA recognizing dipyrrole unit, 7 or 8, starts with the 
trichloroacetylation of N-methylpyrrole.  This compound, 3, has been made on a large scale in 
the laboratory by the reaction of trichloroacetyl chloride with N-methyl pyrrole following 
published procedures.27 Compound 3 is first nitrated using fuming nitric acid with acetic 
anhydride as the solvent as shown in Scheme 3.5.  This nitration results in  
N
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N
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4
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Yield: 84 %
3
 
Scheme 3.5 
the formation of the desired 4-nitro product along with a small amount of the undesired 5-nitro 
isomer.  Carrying out the reaction at low temperatures (- 40 °C), results in improving the yield of 
the desired 4-nitro isomer and minimizing the amount of the unwanted 5-nitro isomer formed.  
Upon completion of nitration, the reaction mixture is quenched with the addition of a specific 
amount of water and stirred overnight, which results in the hydrolysis of the acetic anhydride to 
acetic acid and precipitates the product.  It turns out that the desired 4-nitro isomer is less soluble 
in water than the 5-nitro isomer and therefore, addition of an appropriate amount of water is 
essential for the isolation of pure product in this step.  Addition of too much water results in the 
precipitation of both isomers.  The trichloroacetyl group is stable to aqueous hydrolysis 
especially at room temperature, making this simple aqueous workup possible.    Filtration of the 
precipitate through a büchner funnel then results in almost pure 4 in an 84 % yield.  Occasionally 
small amounts (< 5 %) of the other isomer are also obtained but no attempt is made to further 
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purify the product at this stage because the purification is easily accomplished in subsequent 
steps.  
 The next step of the synthesis was the addition of the linker as described above from 
Scheme 3.1.  The nitropyrrole (4) was reacted with either ethyl 4-aminobutyrate hydrochloride 
(for the synthesis of 5) or with ethyl β-alanine hydrochloride (for the synthesis of 6) by stirring at 
room temperature in EtOAc using TEA as the HCl scavenger as shown in Scheme 3.6.  These 
amines react readily with the trichloroacetyl groups  
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Scheme 3.6 
eliminating chloroform, which can be easily removed by rotary evaporation.  Upon completion 
of the reaction the, insoluble TEA hydrochloride salt can be filtered from the product.  Yields 
were improved by bubbling Ar through the solution of EtOAc and TEA before the addition of 
the linker and 4 and carrying out the reaction under an Ar atmosphere.  The product was purified 
from any unreacted starting material and any of the 5-nitro-N-methylpyrrole formed in the 
previous step, by flash column chromatography to give 5 in an 86 % yield and 6 in a 57 % yield.  
The addition of the second pyrrole unit is the next step of the synthesis and is accomplished as 
shown in Scheme 3.7 below.  The nitro group in 5 or 6 was reduced with H2 gas under high 
pressure in the presence of Pd/C catalyst.  The reaction was followed by TLC and shortly after 
the disappearance of the nitro compound, the reaction was stopped, the catalyst  
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Scheme 3.7 
was filtered off, the solvent was removed by rotary evaporation, and the product was evacuated 
under vacuum overnight.  This intermediate product (presumably the amine) was reacted with 
another unit of 4 in EtOAc at room temperature.  The desired product (7 or 8) fell out of solution 
as a yellow precipitate that was easily filtered off.  The filtrate often contained some more of the 
product which could be precipitated and isolated upon concentration of the solution by rotary 
evaporation followed by cooling in the refrigerator.  The filtered products, the dipeptide esters 7 
and 8 were obtained in yields of 35 % and 32 % respectively.   
 
3.4. Synthesis of the DNA-Recognizing Dipyrrole Component Following Scheme 3.2 
 The alternate method of synthesis outlined in Scheme 3.2, which was developed in order 
to introduce the linker unit at a later stage, also starts with the same compound 3 which is 
nitrated to 4 as described above.  Compound 4 is condensed with commercially available methyl-
4-amino-1-methyl-1H-pyrrole-2-carboxylate, hydrochloride salt, to form the dipyrrole unit 9 as 
shown in Scheme 3.8. The reaction is carried out in EtOAc in the presence of DIEA which 
scavenges the HCl from 4-amino-1-methyl-1H-pyrrole-2-carboxylate, hydrochloride salt to form 
the free amine.  The formation of 9 results in a  
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yellow precipitate that can be filtered.  The product has to be washed with water to remove the 
DIEA hydrochloride salt and dried to give 9 in a 94 % yield. 
 Nitro compound 9 was converted into the olefin by reducing the nitro group into the 
amine and then reacting the amine with acryloyl chloride in the presence of DIEA in THF as 
shown in Scheme 3.9.  The DIEA scavenged the HCl that was formed  
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Scheme 3.9 
upon the reaction of the amine and the acryloyl chloride.  Flash column chromatography was 
used to purify 10 which was obtained in a 71 % yield.   
 Once the methyl ester on 10 is hydrolyzed to the carboxylic acid, various linkers can be 
added.  However, basic hydrolysis of 10 did not result in the desired olefin carboxylic acid 11 as 
shown in scheme 3.10. 
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 NMR analysis was used to determine the identity of the product obtained.  The 1H NMR 
spectra of the starting compound 10 and the product of the hydrolysis reaction are shown in 
Figures 3.6 and 3.7 respectively.  Some of the key features in the 1H NMR spectrum of 10, as 
can be seen from Figure 3.6 a) are the two amide hydrogens around 10 ppm, the 3 olefinic 
hydrogens between 5.5-6.5 ppm, and the 3 methyl singlets between 3.5-4.0 ppm.  In the 1H NMR 
spectrum of the product obtained upon base hydrolysis of 10 (see Figure 3.6 b) the 3 methyl 
singlets are still present indicating that the ester has not been hydrolyzed.  Instead, the olefinic 
hydrogens have disappeared.  It is unlikely that the amide bond next to the olefin has been 
hydrolyzed off since both amide hydrogen peaks are still present at 10 ppm.  It is therefore likely 
that a Michael addition of a hydroxide has taken place at the alkene resulting in the formation of 
compound 12 (Scheme 3.11).  
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a)  
b)  
Figure 3.6. 1H NMR of a) 10 and b) products of reaction of 10 with NaOH.   
 
NHN
O
H3CO
N
HN
O
O
HO 11
10
8
6
7
9
5
4
2
3
1
12
Aromatics  
2,4,6,8       
Amides 5,9  
No alkene 
11
10 
1,3,7 
N
HN
O
H3CO
N
HN
O
O
11
10
9
8
6
7
5
4
2
3
1
10
Amides 5,9 
Aromatics 
2,4,6,8 
Alkenes 10,11 
H2O
DMSO 
1,3,7 
 38
This hypothesis is strengthened by the observation of two new peaks (labeled 10 and 11 in the 
spectrum) seen at 2.4 and 3.5 ppm which could represent the two new CH2 hydrogens.  No 
further attempt was made to identify compound 12. 
 Further base hydrolysis of compound 12 resulted in the loss of one of the methyl groups 
indicating that the ester can be hydrolyzed under more rigorous conditions.  However, in spite of 
attempting the hydrolysis of 10 under numerous different conditions with different reagents, the 
ester was unable to be hydrolyzed while leaving the alkene intact.  Therefore, it was decided to 
add the linker and the targeting glucose unit before the introduction of the olefin in order to 
avoid all hydrolysis reactions after the addition of the olefin.  
 The methyl ester of 9 was then converted to the carboxylic acid with NaOH in EtOH and 
H2O under reflux and then acidified and filtered to give 13 in yields close to 90 % as shown in 
Scheme 3.12.  The carboxylic acid that is formed is yellow, but after drying on the filter paper 
the product often appears to be a dark brown solid.  
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 The linkers can now be added to this nitro dipeptide carboxylic acid unit by standard 
peptide coupling methods.  The coupling reagents that were employed here were EDCI and 
HOBT.  EDCI is a water soluble carbodiimide that makes purification steps simple because it 
can be removed by liquid-liquid extraction.  Figure 3.7 shows the  
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mechanism of action of EDCI and HOBT.  The EDCI activates the carboxylic acid by forming 
the O-acylisourea intermediate.28  
 One complication that is typically seen which reduces yields in these reactions is the 
rearrangement of the O-acylisourea intermediate to give an N-acylurea that is then unreactive 
and cannot be used form the amide bond.28 Use of HOBT prevents this from occurring.  HOBT 
reacts with the O-acylisourea to form another intermediate, which does not undergo 
rearrangement and reacts with the amine to form an amide bond.28-29  It has also been reported in 
literature that the use of CuCl2 as a catalyst further reduces the occurrence of unwanted 
rearrangement reactions,28-29 though the mechanism by which CuCl2 achieves this is not clearly 
understood.   
 The two linkers were added to the dipeptide carboxylic acid 13 as shown in Scheme 3.13.  
Upon formation of the product as indicated by TLC the reaction mixture  
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was diluted with DCM, extracted with dilute base and dilute acid.  Upon cooling the DCM in the 
freezer overnight the products crystallized out of solution to give 7 in a 62 % yield and 8 in a 57 
% yield.   
 The carboxylate esters on the linkers in 7 and 8 had to be hydrolyzed to carboxylic acids 
before they could be coupled to the cell targeting unit.  This hydrolysis is very efficiently 
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achieved using NaOH in EtOH/H2O followed by acidification with yields than 90 % resulting in 
the formation of compounds 14 and 15 as shown in Scheme 3.14.   
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Scheme 3.14 
 Thus compounds 14 and 15 can be obtained following either Scheme 3.1 or 3.2.  
However, Scheme 3.2 has the advantage that the linker is added on at a later stage.  Due to 
complications resulting from the Michael addition at the alkene in 10 during base hydrolysis, the 
linker had to be added at an earlier step than originally planned.  Irrespective of the linker that is 
to be used, compound 13 can now be made on a large scale and then stored and used when 
needed with various linkers.  Other approaches are being explored in the laboratory in which the 
linker can be added further down the line in the synthesis. 
 
3.5. Synthesis of the Cell Targeting Glucose Unit 
 The targeting unit is introduced as D-glucosamine, which has both reactive hydroxyl 
groups and the reactive amine.  The amine will be used in the formation of the amide bond that 
will link the glucose unit to compounds 14 and 15.  In order to prevent interference from the 
hydroxyl groups, they have to be protected while leaving the amine deprotected.  This was 
accomplished as outlined below in Scheme 3.15 following  
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Scheme 3.15 
procedures described in literature.26 First, the amine of D-glucosamine was masked as 4-
methoxybenzylidene using 4-methoxybenzaldehyde with NaOH/water at 0°C.  The product falls 
out of the reactions mixture as a white precipitate upon cooling and can be easily filtered to give 
16 in a 75 % yield.  The OH groups were then protected with acetyl groups using acetic 
anhydride in anhydrous pyridine.  Quenching the reaction with ice water causes the product to 
fall out as a white precipitate which can be filtered out to give 17 in a 79 % yield.  Finally, the 
amine was unmasked by reacting 17 with acetyl chloride dissolved in anhydrous methanol using 
acetone as the solvent.  Upon the addition of ether at the end of the reaction, a white precipitate 
was formed which was filtered out to give the protected glucosamine hydrochloride, 18, in an 81 
% yield.  The overall yield of the three steps was 47.9%.   
 
3.6. Assembly of the DNA Recognizing Unit with the Cell Targeting Glucose Unit 
 The protected glucosamine (18) from above can be coupled with carboxylic acid termini 
of the various linkers.  The coupling reaction is carried out similar to the one described earlier for 
preparing 7 and 8 (Scheme 3.13).  The protected glucosamine was reacted with the carboxylic 
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acid (14 or 15) in the presence of EDCI, HOBT, DMAP, and CuCl2 in DMF as shown in Scheme 
3.16.  The products were isolated by crystallizing  
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Scheme 3.16 
from DCM as described earlier.  The products 19 and 20 were obtained in very high yields (90 % 
and 82 % respectively.) 
 Compounds 19 and 20 incorporate both a DNA recognizing unit, which can recognize the 
A/T rich sequences on DNA, and a cell targeting unit (glucose unit), which upon deprotection of 
the hydroxyl groups should be able to target pancreatic β-cells through the GLUT-2 transporters.  
The next stage of the synthesis is to functionalize the N-terminus of the pyrrole dipeptide unit as 
the methyl sulfonate, which will serve as the DNA methylating agent (see Scheme 3.4). 
  The nitro group of 19 and 20 was reduced to the amine and reacted with acryloyl 
chloride in the presence of DIEA in THF as shown in Scheme 3.17 to form the olefin  
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products 21 and 22.  Thus the olefinic functionality, which underwent Michael addition if 
introduced earlier, has now been attached to the molecules.  The products were then either 
crystallized out of the DCM or purified by flash column chromatography was to obtain 21 (37 %) 
and 22 (63 %).   
 These reactions of converting the nitro into the alkene typically give much higher yields 
in the absence of the sugar unit.  For example, compound 7 when reacted under the same 
conditions as described above, gives the alkene compound 23 in a 91 % yield (Scheme 3.18).  
Similarly 9 can be converted into 10 in a 71 % yield (see Scheme 3.9).   
 However, with the sugar attached, the yields for these reactions were much lower.  These 
reactions are being further optimized in the laboratory. 
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3.7. Introduction of the DNA Alkylating Methyl Sulfonate Group  
   The next step in the synthesis was to convert the alkene double bond into the sulfonic 
acid, and this is accomplished by the anti-Markovnikov addition of bisulfite (NH4HSO3) across 
the alkene double bond.  This reaction is believed to proceed by a radical mechanism.  
Compound 21 was reacted with NH4HSO3 and H2O2 in 25 % THF/H2O under reflux and then 
acidified as shown in Scheme 3.19.  After flash column  
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Scheme 3.19 
chromatography, a product was isolated as a yellow colored solid.  Earlier procedures described 
in literature used DMF as a solvent.10 However, the isolation of the product is more difficult 
when DMF is used and employing THF as solvent makes the purification and isolation of the 
product simpler.    
 46
 The 1H NMR spectra of 21 and the product of the reaction are shown in Figure 3.8 a) and 
b) respectively with all the key characteristics identified.  The three olefinic hydrogens (5.7-6.3 
ppm), the four different acetyl methyl hydrogens (1.9-2.0 ppm), the two aromatic amide 
hydrogens (9.8-10.0 ppm), and the two aliphatic amide hydrogens (8.0 ppm) can be clearly 
identified in the spectrum of 21 (Figure 3.8 a)) in which all the peaks are well resolved.  The 1H 
NMR spectrum of the product (Figure 3.8 b)) shows the disappearance of the alkene hydrogen 
peaks and the characteristic shifts of the CH2CH2 hydrogens next to the sulfonic acid between 
2.6-2.8 ppm.  However, in this spectrum there are more peaks than expected in the region where 
the acetyl methyl hydrogens of the protecting groups show up (1.8-2.2 ppm) and the sugar 
hydrogens are not well resolved.  It is therefore possible that there is some level of deprotection 
of the acetyl groups, or epimerization of the sugar unit resulting in a mixture of compounds in 
the product that was isolated.  This may have been caused by the treatment with concentrated 
HCl used in the acidification of the sulfonate salt.  Therefore, the identity of 25 is yet to be 
confirmed and further purification of the product is also being attempted.  
 Since it seemed possible that some deprotection of the hydroxyl groups on the glucose 
unit was taking place possibly due to the treatment with strong acid, it was decided to attempt the 
deprotection reaction directly on the sulfonate salt before acidification.  This deprotection can be 
easily accomplished by treatment with 7 N NH3 in methanol, a procedure that was tested with 
compound 19 as shown in Scheme 3.20. 
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a)   
b)  
Figure 3.8.  1H NMR of a) 21 and b) product of reaction of 21 with NH4HSO3 and H2O2. 
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Scheme 3.20 
The ammonia treatment of this compound results in the complete deprotection of the glucose unit 
and formation of 26, as can be verified by a comparison of the 1H NMR spectra of the two 
compounds 19 and 26 shown in Figures 3.9 a) and b) respectively.  However, when this 
treatment was applied to the product of the reaction shown in Scheme 3.19, the expected well 
resolved 1H NMR spectrum was not obtained.  This procedure is still under investigation in the 
lab.   
 An alternate procedure for the conversion of an alkene to the sulfonic acid, using 
NaHSO3 in EtOH/H2O at a basic pH, which is described in literature was tested.30 Using this 
procedure, 23 can be converted to the sulfonic acid, 27, as shown in Scheme 3.21 in a yield of 89 
%.  Surprisingly, under these basic reaction conditions, no Michael addition product is obtained.  
The use of these reaction conditions on compound 21 can, in principle, result in the conversion 
of the alkene into the sulfonic acid and the removal of 
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a)  
 
b)  
Figure 3.9. 1H NMR spectrum of a) 19 and b) 26 
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Scheme 3.21 
the acetyl protecting groups on the glucose unit in a single step as shown in Scheme 3.22.  This 
reaction is under investigation in the laboratory. 
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Scheme 3.22 
 There is evidence in literature that compounds containing both a sulfonic acid and a 
carboxylic acid can be reacted with amines under certain conditions which can result in the 
formation of an amide bond without complications due to the presence of the sulfonic acid.31 
This reaction was verified by coupling carboxylic acid 14 with 18 in the presence of equivalent 
amounts of the sodium salt of hexane sulfonic acid as shown in Scheme 3.23.  This reaction 
resulted in the formation of 19 in excellent yields.  Therefore, ester  
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Scheme 3.23 
27 was hydrolyzed to the carboxylic acid as shown in Scheme 3.24 in an 81 % yield.   
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Scheme 3.24 
Subsequently, one equivalent of NaOH was added to the sulfonic acid carboxylic acid 29, and 
the coupling reaction with the protected glucosamine 18 was attempted as outlined in Scheme 
3.25.  The initial attempt was inconclusive and this reaction is being further explored in the 
laboratory.  
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Scheme 3.25 
 If the coupling of 18 to a sulfonic acid carboxylic acid can be successfully accomplished, 
it would offer a tremendous advantage for the overall synthesis since compound 30 (Figure 3.10) 
could be prepared which could then be coupled with the appropriate linker when needed.  The 
ester on the linker could then be hydrolyzed and coupled with glucosamine, this making the 
overall synthesis of molecules with several linkers very efficient.  
 Once the desired sulfonic acid compound (28) with the deprotected glucose unit is 
prepared by one of the above methods, the reactive methyl group has to be introduced.  The 
sulfonic acid is typically converted to the methyl sulfonate by treatment with 3-methyl-p-
tolyltriazine in anhydrous dioxane.  For example compound 31 (with one imidazole and one 
pyrrole ring) to compound 33 following procedures outlined in  
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Scheme 3.26.  This reaction gives the product 33 in a 57 % yield after purification by flash 
column chromatography. 
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Scheme 3.26 
.  In order to verify that the hydroxyl groups on the glucose unit in the compounds are 
unaffected under these reaction conditions, the reaction was attempted on a test compound 16 as 
shown in Scheme 3.27.  No reaction was obtained in this case and  
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Scheme 3.27 
compound 16 was isolated intact from this reaction.  This indicated that the OH groups on the 
glucose unit would not get methylated under the conditions used to convert the sulfonic acid to 
the methyl sulfonate.   
 The synthesis is two steps away from completion and will then be ready for testing with 
DNA to determine the methylation ability of the compounds on the DNA.  Promising 
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possibilities for introducing the linker at a late stage in the overall synthesis is being further 
investigated to find the best way to construct these types of compounds with different linkers 
attached. 
   
CHAPTER 4. DESIGN, SYNTHESIS, AND CHARACTERIZATION OF NEW DNA MINOR 
GROOVE BINDING FLUORESCENT PROBES 
 57
4.1. Design 
The binding of the Me-lex component of the new molecules to the DNA minor groove at 
A/T rich regions is expected to be critical for their ability to methylate DNA.  The new 
compounds are, by design, weak DNA binders so that upon transferring the methyl group to 
DNA (which results in a negative charge on the molecule) they will depart without further 
interacting with the DNA.  This would ensure that the biological outcomes observed are due to 
the methylation alone, and not due to other interactions between the molecules and DNA.  
However, the strength of binding will be directly correlated to the levels of methylation observed 
in these concerted alkylation reactions, and therefore sufficient strength of binding is necessary 
in order to achieve efficient methylation.  Therefore, it was also decided to develop an assay to 
determine the DNA binding of these new compounds and understand how the binding is 
influenced by the attachment of the various linkers and the glucose unit to the Me-lex unit.  This 
knowledge would enable the efficient design and synthesis of compounds which are likely to 
have a high chance of success in methylating DNA with the targeting ligand, glucose attached. 
 Fluorescence assays have been described in literature for measuring binding constants of 
compounds which bind to the DNA minor groove at A/T rich regions.  For example, in the 
fluorescent compound Hoechst 33258 (Figure 4.1 a)) that binds to the A/T rich minor groove 
regions of DNA is used to measure the binding constants of compounds like netropsin and 
distamycin (Figure 4.1 b) and c)), which bind to the same sites on DNA.32 The fluorescence 
properties of Hoechst 33258 when bound within the minor groove of DNA are different from 
those when it is free in solution.32  This  
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Figure 4.1. Structure of a) netropsin b) distamycin and c) Hoechst 33258. 
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difference in fluorescence has been used to determine the binding constants of the different 
compounds that compete for the same binding site.   
 The fluorescence assay described above is well suited for this study.  However, the 
fluorescent probe used, Hoechst 33258, is a strong DNA binder (Kb > 107) while the compounds 
being investigated in this project are weak binders (Kb ≈ 105) by design.  Therefore, it is unlikely 
that the compounds being tested can displace the Hoechst 33258 from the binding site.   
 In order to use this assay to determine the binding of the new compounds, a fluorescent 
probe is needed whose strength of binding to the desired target site is comparable to the binding 
strength of the compound being tested.  An extensive survey of literature did not lead to the 
identification of a suitable compound.  Therefore, it was decided to synthesize new fluorescent 
probes suitable for the study. 
 In order to design new fluorescent probes that would target the A/T rich sites in the minor 
groove of DNA it was decided to use the same DNA recognizing dipyrrole units as the 
compounds described in CHAPTER 3 and attach a fluorophore either at the C-terminus or the N-
terminus of these compounds.  Coumarin was selected as the fluorophore to be attached because 
of its favorable fluorescence properties, water solubility, and relatively planar structure which 
would enable it to slide within the DNA minor groove with minimal steric problems.  The mode 
of attachment of the coumarin to the DNA recognizing dipyrrole units is important because the 
resultant compounds must retain their ability to bind to the minor groove at A/T rich regions of 
DNA, exhibit good fluorescence properties in solution, and exhibit a change in fluorescence 
when bound to DNA.  With these characteristics in mind, four new compounds were designed 
and are shown in Figure 4.2 a)-d).  In two of the compounds (41, 42) the appropriate coumarin is 
attached at the C-terminus of the dipyrroles and the other two (34, 36) the coumarin component 
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is attached to the N-terminus of the dipyrroles.  If one of these compound exhibits sufficient 
binding to the target site and exhibits a change in fluorescence properties upon biding to the 
DNA, it can be used as a probe to investigate the DNA-binding ability of the various compounds 
and intermediates prepared in this project.   
   
4.2. Synthesis 
 The synthesis of the fluorescent probes involved the attachment of the appropriate DNA 
recognizing dipyrrole component to the appropriate coumarin component.  The two coumarin 
components that were used are shown in Figure 4.3 a) and b).  When the coumarin was to be 
connected to the N-terminus, as in compounds 34 and 36, coumarin-3-carboxylic acid (Figure 
4.3 a)) was used.  When the coumarin unit was to be connected to the C-terminus, as in 
compounds 39 and 43, 7-amino-4-methylcoumarin (Figure 4.3 b)) was used. 
 Compound 34 was prepared earlier in the laboratory by condensation of 9 with coumarin 
-3-carboxylic acid as shown in Scheme 4.1.  The nitro group on 9 was first  
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Figure 4.2.  a) Coumarin attached at the N-terminus with a methyl ester at the C-                     
terminus.   
                   b) Coumarin attached at the N-terminus with a propylamide at the C-  
                    terminus.   
   c) Coumarin attached at the C-terminus with an acetamide at the N-    
    terminus.   
       d) Coumarin attached at the C-terminus with a four carbon linker with an  
        acetamide at the N-terminus. 
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reduced to the amine and used for the next step without isolation.  The amine was then reacted 
with the coumarin-3-carboxylic acid with the coupling reagents EDCI, HOBT, DMAP, and 
CuCl2 in DMF to give 34.   
 The synthesis of compound 36 was accomplished in three steps starting from compound 
13 as shown in Scheme 4.2.  The first step was a coupling reaction with 13 and N-propylamine 
using the coupling reagents EDCI, HOBT, DMAP, and CuCl2 in DMF to give 35 in a 55 % yield.  
The next step involved a reduction of the nitro on 33 to  
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Scheme 4.2 
the amine as in Scheme 4.2, and the last step was a coupling reaction with coumarin-3-
carboxylic acid and the amine using the same coupling reagents as above to give 36 in a 42 % 
yield.  This compound has a propylamide group on the C-terminus of the compound instead of a 
methylester as in 34.  This variation could make a difference in binding with DNA because of the 
amide NH on 36 that can form hydrogen binding in the minor groove of DNA. 
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 In order to synthesize compounds 41 and 42, which have the coumarin units attached to 
the C-terminus, the N-terminus had to be first converted to an amide in order to contribute 
favorably to the DNA binding.  In order to do this, the nitro group on 9 was first reduced to the 
amine and acetyl chloride was used to form an acetamide at the N-terminus to give 37 in a 58 % 
yield as shown in Scheme 4.3.  The next step was a hydrolysis of the methylester to give the 
carboxylic acid 38 in a quantitative yield.   
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Scheme 4.3 
In order to prepare compound 42 the nitro group on 7 was first reduced to the amine and acetyl 
chloride was used to form an acetamide at the N-terminus to give 39 in a 43 % yield as shown in 
Scheme 4.4.  The next step was a hydrolysis of the ethylester to give  
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Scheme 4.4 
the carboxylic acid 40 in a 93 % yield.  However, attempts to couple 7-amino-4- methylcoumarin 
with carboxylic acids 38 and 40 (Scheme 4.5) have so far been  
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Scheme 4.5 
unsuccessful, probably due to the unreactive nature of the 7-amino-4-methylcoumarin because of 
the lone pair of electrons on the amine being able to be delocalized into the rings of the 
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compound.  Further efforts to accomplish this coupling reaction are currently in progress in the 
lab. 
 Coumarin-3-carboxylic acid itself is not very fluorescent, but as been reported to become 
fluorescent when the carboxylic acid is converted into an amide.  In order to verify that this is 
indeed the case, compound 43 was made in a 69 % yield by condensing coumarin-3-carboxylic 
acid with N-propylamine using EDCI as the coupling reagent as shown in Scheme 4.6.  
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4.3. Characterization of Spectral Properties 
 Compounds 34 and 36 in which the coumarin was attached to the N-terminus of the 
dipyrrole units were investigated further to see if they were suitable as fluorescent probes for the 
DNA binding assays.  Coumarin-3-carboxylic acid, which was condensed with the amine on the 
dipyrrole units to form 34 and 36, fluoresces very weakly.  In order to verify that conversion of 
this compound into an amide results in a fluorescent compound, the fluorescence properties of 43 
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Figure 4.4. UV absorption spectra of a) coumarin-3-carboxylic acid and b) 43 at 10 µM in 
MeOH.  
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were tested.  The UV spectra of coumarin-3-carboxylic acid and 43 are shown in Figure 4.4 a) 
and b) respectively.  The carboxylic acid has a absorbance maxima at 284 and 317 nm, while the 
amide 43 has a absorbance maxima at 299 and 333 nm.  These compounds were excited at 300 
nm in a pH 7 buffer solution at 10 µM concentration, and the fluorescence spectra of the 
compounds are shown in Figure 4.5.  As can be seen from the figure, conversion of the 
carboxylic acid to a simple amide results in a compound with strong fluorescence.         
 UV absorption spectra of compounds 34 and 36 are shown in Figure 4.6.  The absorption 
profile of these two compounds was compared with the absorption profile of compound 38 
(Figure 4.7, dipyrrole unit without attached coumarin) and that of the coumarin amide 43 (Figure 
4.4 b)) in order to identify the absorption due to the coumarin unit in compounds 34 and 36.  
This absorption maximum due to coumarin can then be used to determine the excitation 
wavelength for the fluorescent studies.  However, neither compound (34 or 36) showed a strong 
absorbance attributable only to the coumarin unit.  Both compounds had an absorption maximum 
around 300 nm and this wavelength was used as the excitation wavelength in the fluorescence 
experiments.   
 The fluorescence spectra of compounds 34 and 36 when excited at 300 nm in the pH 7 
buffer solution at 10 µM concentration are shown in figure 4.8 a) and b) respectively.  As can be 
seen from the figure, neither compound fluoresces strongly.  The reason for this lack of 
fluorescence is not clear.  Perhaps there is a lack of fluorescence due to the extended conjugation 
of the coumarin with the dipyrrole unit. 
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Figure 4.5. Fluorescence of a) coumarin-3-carboxylic acid and b) of 43 in MeOH at 10 µM 
concentration excited at 300 nm. 
Expanded view 
43 
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Figure 4.6. UV absorption spectra of a) 34 and b) 36 at a 10 µM concentration in MeOH. 
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Figure 4.7. UV absorption spectrum of 38 at a 10 µM concentration in MeOH. 
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Figure 4.8. Fluorescence of a) 34 and b) 36 in buffer at 10 µM excited at 300 nm. 
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 In order to test whether pyrrole compounds directly quench the fluorescence or whether 
the mode of connection of the coumarin unit to the pyrrole unit is responsible for the weak 
fluorescence of compounds 34 and 36, 7-hydroxy-4-methylcoumarin (a model compound which 
fluoresces strongly) was titrated with compound 38, and the change in fluorescence was recorded 
as shown in Figure 4.9.  Aliquots of a 20 mM solution of 38 were added to a 10 µM MeOH 
solution of 7-hydroxy-4-methylcoumarin in MeOH.  Each addition of 38 reduced the 
fluorescence intensity as shown in Figure 4.9.  This decrease in fluoresce could be either due to 
quenching by compound 38, or due to excitation wavelength intensity being filtered out due to 
absorption by increasing amounts of 38.  If fluorescence of 7-hydroxy-4-methylcoumarin is 
indeed being collisionally quenched by 38, then a plot of Fo/F versus concentration of compound 
38 (where Fo is the fluorescence observed in the absence of 38 and F is the fluorescence 
observed at a particular concentration of 38) should be a straight line.  If there is a complex 
formation, a curved line can result.  As can be seen from Figure 4.10, this plot is not a straight 
line.  If the reduction in fluorescence is due to excitation intensity being filtered out by 
increasing concentration of 38, then a plot of the increase in UV absorbance at 330 nm 
(excitation wavelength) versus the decrease in fluorescence should be a straight line.  The 
variation in the UV absorption profile upon addition of varying amounts of 38 is shown in Figure 
4.11, and the plot of the change in absorbance versus the change in fluorescence is shown in 
Figure 4.12.  Since this plot is a straight line, the decrease in fluorescence must be due to the 
filtering out of excitation wavelength intensity by increasing amounts of 38, where 38 is 
absorbing all the incident light intensity. 
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Figure 4.9. Fluorescence titration of compound 38 into a 10 µM solution of 7-hydroxy- 
                  4-methylcoumarin to show any fluorescent quenching excited at 330 nm. 
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Figure 4.10. Fo/F vs. concentration of 38, where Fo is the fluorescence observed in the absence of 
38 and F is the fluorescence observed at a particular concentration of 38. 
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Figure 4.11. Variation in the UV absorption at varying concentrations of 38 in MeOH.
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Figure 4.12. A-Ao of 38 vs. Fo-F of 7-hydroxy-4-methyl coumarin titrated with 38, where A is 
the absorption of 38 at varying concentrations, Ao is the absorption with no 38, Fo is 
the fluorescence observed in the absence of 38, and F is the fluorescence observed at 
a particular concentration of 38. 
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 Since the mode of connection of coumarin to the dipyrrole unit appears to be responsible 
for the lack of fluorescence, it is possible that the introduction of methylene units between the 
coumarin and the dipyrroles, or the connection of the coumarin to the C-terminus (as in 
compounds 41 and 42) may result in fluorescent compounds that can be investigated for use as 
probes for measuring DNA binding.  The syntheses of such compounds are currently ongoing in 
the lab. 
CHAPTER 5. EXPERIMENTAL 
 80
5.1. General 
 All solvents and reagents were purchased from VWR International (West Chester, 
Pennsylvania) or Sigma-Aldrich (Atlanta, Georgia) and were of the highest grade available 
unless otherwise noted.  Flash chromatography was performed with silica gel (230/400 mesh, 
Life Force Inc.).  TLC was performed on glass plates coated with silica gel (Whatman 
International, Maidstone, England, 150 A) that had a fluorescence indicator and were detected by 
UV visualization.  All rotary evaporations were carried out using a Buchi R-3000 or a Buchi R-
114 rotary evaporator equipped with a Brinkmann model B-16 vacuum aspirator.  
Hydrogenations were performed using a Parr Hydrogenation Apparatus in a 500 mL Parr jar. 
Melting points were determined using a Mel-Temp II. 
 All anhydrous reactions were carried out under positive pressure of argon.  Glassware 
used for anhydrous reactions were dried overnight in an oven at 140 °C or dried over a flame, 
assembled while still hot, and cooled to room temperature under argon.  Solvents and reagents 
(liquids) for anhydrous reactions were obtained in bottles with sure-seal caps and transferred by 
using oven-dried needles and glass syringes. 
 All 1H NMR and 13C NMR spectra were recorded with a Bruker Avance 400 MHz 
NMR spectrometer, using deuterated DMSO as the solvent.  The deuterated DMSO was obtained 
in sealed ampoules from ACROS Organics or Sigma-Aldrich.  The spectra are reported in ppm 
and referenced to deuterated DMSO (2.49 ppm for 1H, 39.5 ppm for 13C).  The samples were 
contained in 5 mm pyrex glass tubes obtained from Wilmad- LabGlass Buena, New Jersey. 
 Ultraviolet absorbance analyses were performed on a Cary 1E UV-Visible 
spectrophotometer.  Fluorescence emissions were recorded on a SLM 8100 spectrofluorometer. 
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5.2. Fluorescence Methods 
 5.2.1. Solutions of Compounds for UV and Fluorescence   
All compounds were accurately weighed with 10 mg or more and dissolved in known 
volumes of appropriate solvents in order to make stock solutions of exact concentrations.  All 
compounds were first dissolved in methanol except 34, which was first dissolved in 1 mL of 
DMSO and then diluted into methanol.  The final percentage of DMSO when used was always 
less than 0.3 % of the total volume.  The stock solutions were diluted with a 0.01 M potassium 
phosphate buffer, pH 7.0, 0.01 M NaCl to a final concentration of 10 µM.  These solutions of the 
compounds were used for UV and fluorescence experiments. 
  
 5.2.2. UV and Fluorescence Experiments 
 UV absorption wavelengths were scanned from 200 nm to 500 nm of each of the 10 µM 
solutions in the 0.01 M potassium phosphate buffer, pH 7.0, 0.01 M NaCl to find the absorption 
maxima.  The excitation wavelength for all the compounds was set at 300 nm and the 
fluorescence was scanned from 330 nm to 500 nm. 
 For the titration of 38 with 7-hydroxy-4-methylcoumarin, the fluorescence was taken of a 
10 µM solution of 7-hdyroxy-4-methylcoumarin.  Aliquots of 2.5 µL of a solution containing 38 
at 20 mM and 7-hydroxy-4-methylcoumarin at 10 µM in MeOH were titrated in until 38 was at 
300 µM.  Thereby each addition did not change the concentration of 7-hydroxy-4-
methylcoumarin; however each addition changed the concentration of 38.  The excitation 
wavelength was 330 nm and the fluorescence was measured from 350 to 500 nm.     
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5.3. Synthesis 
 2,2,2-trichloro-1-(1-methyl-1H-pyrrol-2-yl)ethanone (3).  This compound was 
prepared earlier in the laboratory using methods described in literature.27 
 2,2,2-trichloro-1-(1-methyl-4-nitro-1H-pyrrol-2-yl)ethanone (4).  Pyrrole 3 (5.00 g, 
0.0220 mol) was dissolved in acetic anhydride (50.0 mL) in a 250 mL round bottom flask and 
cooled to -40 ºC in a dry ice/acetone bath.  Fuming nitric acid (2.5 mL) was added dropwise over 
5 minutes with constant stirring  while keeping the temperature of the reaction mixture lower 
than -30 °C by periodic addition of dry ice to the acetone bath.  After the addition of HNO3, the 
mixture was stirred for another 45 minutes at -40 °C.  The solution was then allowed to warm to 
room temperature and was stirred for an additional hour.  The solution was then cooled in an ice 
bath and then water (30 mL) was added slowly over one minute.  A yellow solid precipitated and 
was filtered under vacuum and dried to give 4 (5.04 g, 84%): mp 112-120 ºC. TLC (1:1, 
EtOAc:Hexane) Rf = 0.58.  1H NMR data: δ 8.56 (d, J = 1.73 Hz, 1H), 7.78 (d, J = 1.71 Hz, 1H), 
3.98 (s, 3H).  13C NMR data: δ 173.30, 134.73, 133.09, 121.09, 116.82, 95.02, 79.44. 
 Ethyl 4-{[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}butanoate (5).   The 
nitro pyrrole 4 (8.00 g, 0.0352 mol) was dissolved in EtOAc (420 mL) and TEA (10 mL) was 
added while Ar was bubbled through the solution.  Aminobutyrate hydrochloride (5.90 g, 0.0353 
mol) was then added and the solution was allowed to stir overnight under Ar.  The white 
precipitate that was formed was filtered off and the filtrate was concentrated by rotary 
evaporation to give a brown oil.  The oil was kept under vacuum until a yellow solid formed to 
give 5 (8.58 g, 86%): mp 55-60 ºC.  TLC (1:1, EtOAc:Hexane) Rf = 0.27.  1H NMR data: δ 8.39 
(t, J = 5.37, 5.41 Hz,1H), 8.11 (d, J = 1.67 Hz, 1H), 7.41 (d, J = 1.93 Hz, 1H), 4.02 (q, J = 7.12, 
7.11, 7.11 Hz, 2H), 3.88 (s, 3H), 3.19 (q, J = 6.72, 6.04, 6.65 Hz, 2H), 2.33 (t, J = 7.4, 7.38 Hz, 
 83
2H), 1.73 (p, J = 7.17, 7.15, 7.15, 7.13 Hz, 2H), 1.16 (t, J = 7.10, 7.11 Hz, 3H).  13C NMR data: δ 
172.65, 159.85, 133.75, 127.85, 126.42, 107.30, 59.80, 37.94, 37.38, 30.97, 24.38, 14.11. 
Ethyl N-[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]-β-alaninate (6).  Compound 6 
was synthesized by a similar procedure similar to the one described above for 5 using 4.00 g 
(14.8 mmol) of 4 and 2.70 g (17.8 mmol) of β-alanine ethyl ester hydrochloride to obtain 6 (2.79 
g, 57 %): mp 128-129 °C. TLC (2:1, EtOAc:Hexane) Rf = 0.45.  1H NMR data: δ 8.48 (t, J = 
5.37, 5.42 Hz, 1H), 8.12 (d, J = 1.88 Hz, 1H), 7.39 (d, J = 2.00 Hz, 1H), 4.05 (q, J = 7.11, 7.11, 
7.13 Hz, 2H), 3.88 (s, 3H), 3.40 (q, J = 6.90, 5.61, 6.85, 2H), 2.53 (t, J = 6.90, 6.93 Hz, 2H), 1.16 
(t, J = 7.12, 7.14 Hz, 3H). .  13C NMR data: δ 171.20, 159.87, 133.74, 127.94, 126.23, 107.42, 
59.99, 37.38, 34.95, 33.63, 14.09. 
 Ethyl 4-{[(1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-1H-
pyrrol-2-yl)carbonyl]amino}butanoate (7). Following Scheme 3.1 the nitro pyrrole ester 5 
(2.28 g, 8.06 mmol) was dissolved in ethanol (70 mL) in a 500 mL parr jar and Pd/C (2.00 g) 
was added to it.  The mixture was shaken in a hydrogenator under pressurized hydrogen (60 psi) 
until the reaction was complete as indicated by TLC (EtOAc in 45 min.).  The Pd/C was filtered 
out through celite, and the filtrate was concentrated by rotary evaporation and kept under 
vacuum overnight to yield a yellow solid.  Ethyl acetate (20 mL) was added to this solid in a 250 
mL round bottom flask and the nitro pyrrole 4 (2.20 g, 8.00 mmol) was added and the mixture 
was allowed to stir for 48 hours during which time an orange solid fell out of solution.  After the 
reaction was complete as indicated by the disappearance of the starting material by TLC (4:1, 
EtOAc:MeOH), the orange product that fell out of solution was vacuum filtered to give pure 7 
(1.15 g, 35.1%).   
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Alternate procedure following Scheme 3.2: In a flask flushed with Ar, DMAP (3.48 g, 
2.5 eq.), EDCI (3.38 g, 1.5 eq.), HOBT (5.24 g, 3 eq.), CuCl2 (0.153 g, 0.1 eq.), ethyl-4-
aminobutyrate, HCl (1.91 g, 0.114 mol), and the carboxylic acid 10 (3.33 g, 0.0114 mol) were 
added.  The solid mixture was dissolved in 75 mL anhydrous DMF and allowed to stir under Ar 
overnight at which time TLC (EtOAc) indicated the complete disappearance of 10.  The solution 
was diluted with 150 mL DCM and the organic solution was extracted with H2O (2x 150 mL), 
saturated NaHCO3 (2x 200 mL), and 1M HCl (2x 200 mL).  The organic layers were dried over 
MgSO4.  The solution was concentrated on a rotary evaporator until the volume reduced to 
approximately 20 mL.  This solution was then cooled in the freezer overnight when yellow 
crystals formed.  The yellow crystals were vacuum filtered to give pure 7 (2.86 g, 62 %): mp 
140-143ºC. TLC (EtOAc) Rf = 0.67. 1H NMR data: δ 10.24 (s, 1H), 8.19 (s, 1H), 8.09 (t, J = 5.4, 
5.59 Hz, 1H), 7.58 (t, J = 1.72, 1.45 Hz, 1H), 7.20 (s, 1H), 6.86 (t, J = 1.64, 1.48 Hz, 1H), 4.19 (q, 
J = 7.12, 7.10, 7.13 Hz, 2H), 4.04 (s, 3H), 3.80 (s, 3H), 3.18 (q, J = 6.47, 6.30, 6.22 Hz, 2H), 2.32 
(t, J = 7.51, 7.45 Hz, 2H), 1.73 (p, J = 7.00, 7.09, 7.12, 7.04 Hz, 2H), 1.17 (t, J = 7.12, 7.12 Hz, 
3H).  13C NMR data: δ 173.09, 161.55, 157.21, 134.16, 128.60, 126.68, 123.55, 121.70, 118.35, 
107.92, 104.39, 60.13, 51.64, 37.86, 36.41, 31.42, 25.07, 14.49. 
Ethyl N-[(1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-1H-
pyrrol-2-yl)carbonyl]-β-alaninate (8).  Compound 8 was synthesized following Scheme 3.1 
using a procedure similar to the one described above for 7 using 2.11 g (7.87 mmol) of 5 and 
2.149 g (7.87 mmol) of 4 to give 8 (0.975 g, 32 %).  
Following the alternate procedure in Scheme 3.2 compound 8 was made similar to the 
one described above for 7 using 0.5802 g (19.9 mmol) of 10 and 0.3216 g (19.9 mmol) of β-
alanine ethyl ester hydrochloride to obtain 8 (0.443 g, 57 %): mp 200-201 °C. TLC (EtOAc) Rf = 
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0.62.  1H NMR data: δ 10.22 (s, 1H), 8.16 (d, J = 1.20 Hz, 1H), 8.10 (t, J = 5.44, 5.58 Hz, 1H), 
7.57 (d, J = 1.88 Hz, 1H), 7.20 (d, J = 1.54 Hz, 1H), 6.83 (d, J = 1.68 Hz, 1H), 4.05 (q, J = 7.11, 
7.11, 7.12 Hz, 2H), 3.94 (s, 3H), 3.79 (s, 3H), 3.39 (q, J = 6.78, 5.89, 6.74 Hz, 2H), 2.52 (t, J = 
6.92, 7.04 Hz, 2H), 1.70 (t, J = 7.10, 7.13 Hz, 3H).  13C NMR data: δ 171.44, 161.24, 156.91, 
133.85, 128.27, 126.34, 123.03, 121.44, 118.17, 107.62, 104.17, 59.96, 37.54, 36.10, 34.89, 
34.07, 14.15. 
 Methyl 1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-1H-pyrrole-
2-carboxylate (9).  Argon was bubbled through 50 mL EtOAc containing 3.67 mL DIEA.  
Methyl 4-amino-1-methyl-1H-pyrrole-2-carboxylate, HCl (2.49 g, 0.0131 mol) was then added 
to the solution followed by the addition of the nitro compound 4 (3.58 g, 0.0131 mol) and the 
solution was allowed to stir under Ar for two days.  The yellow solid that was formed, was 
filtered out, washed with H2O, and dried under vacuum to afford the yellow solid 9 (4.05 g, 94 
%): mp 231-235 °C.  TLC (2:1, EtOAc:Hexane) Rf = 0.33 .  1H NMR data: δ 10.26 (s, 1H), 8.18 
(d, J = 1.85 Hz, 1H), 7.54 (d, 1.98 Hz, 1H), 7.45 (d, 1.92 Hz, 1H), 6.87 (d, 1.96 Hz,1H), 3.94 (s, 
3H), 3.83 (s, 3H), 3.73 (s, 3H).  13C NMR data: δ 160.73, 156.94, 133.81, 128.36, 122.15, 120.86, 
118.85, 108.28, 107.66, 51.06, 37.47, 36.28.   
Methyl-4-({[4-(acryloylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl}amino)-1-methyl-
1H-pyrrole-2-carboxylate (10).  Compound 9 (0.454 g, 10.4 mmol) was dissolved in 50 mL 
EtOH and 100 mg Pd/C was added in a parr jar.  The mixture was shaken under pressurized 
hydrogen (75 psi) until 9 had disappeared as indicated by TLC (EtOAc).  The Pd/C was filtered 
out through celite, and the solution was rotary evaporated and the residue was kept under 
vacuum overnight.  The flask with the residue was flushed with Ar and the residue was dissolved 
in anhydrous THF (5 mL) and anhydrous DIEA (0.418 mL) was added to the solution.  The 
 86
solution was bubbled with Ar and cooled to -40 °C.  Acryloyl chloride (0.156 mL) was added 
dropwise to the solution which as then allowed to stir below -20 °C, protected from light, until 
the reaction was complete as indicated by TLC (EtOAc).  The solution was concentrated by 
rotary evaporation and the product was isolated by flash column chromatography (EtOAc) to 
afford pure 10 (0.387 g, 71 %): mp 199-203 °C.  TLC (EtOAc) Rf = 0.43.  1H NMR data: δ  
10.10 (s, 1H), 9.92 (s, 1H), 7.45 (d, J = 2.00 Hz, 1H), 7.25 (d, J = 2.00 Hz, 1H), 6.91 (d, J = 2.00 
Hz, 1H), 6.88 (d, J = 2.00 Hz, 1H), 6.35 (m, 1H), 6.17 (dd, J = 2.00, 15.2 Hz, 1H), 5.65 (dd, J = 
2.4, 7.60 Hz, 1H), 3.82 (s, 6H), 3.72 (s, 3H).  13C NMR data: δ  161.71, 160.86, 158.38, 131.55, 
125.70, 122.92, 121.84, 120.84, 118.64, 108.40, 104.16, 79.54, 78.44, 51.04, 36.25, 36.23.   
1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-1H-pyrrole-2-
carboxylic acid (13).  The nitro ester 9 (4.00 g, 0.0131 mol) was suspended in EtOH (200 mL), 
and a solution of NaOH (2.1 g, 4 eq.) in H2O (150 mL) was added.  This suspension was allowed 
to reflux until the disappearance of 9 was indicated by TLC (EtOAc).  The solution was 
concentrated by rotary evaporation to remove the majority of the EtOH.  The aqueous solution 
was cooled in an ice bath and then acidified with concentrated HCl until the final pH was 
approximately 1 when a precipitate fell out of solution.  The mixture was allowed to cool in the 
freezer for a further two hours, and the yellow solid precipitate was filtered out and rinsed with 
ice cold water and air-dried to give pure 13 (3.33 g, 87 %): mp 200-202 °C.  TLC (EtOAc) Rf = 
0.56.  1H NMR data: δ 12.24 (s, 1H), 10.27 (s, 1H), 8.18 (d, J = 1.84 Hz, 1H), 7.56 (d, J = 1.95 
Hz, 1H), 7.41 (d, J = 1.86 Hz, 1H), 6.83 (d, J = 1.96 Hz, 1H), 3.94 (s, 3H), 3.82 (s, 3H).  13C 
NMR data: δ 161.88, 156.88, 133.81, 128.29, 126.17, 121.89, 120.39, 119.84, 108.30, 107.65, 
37.47, 36.24. 
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4-{[(1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-1H-pyrrol-2-
yl)carbonyl]amino}butanoic acid (14).  Compound 7 (1.00 g, 2.46 mmol) was dissolved in 
ethanol (28 mL) at room temperature in a 250 mL round bottom flask.  To this solution, KOH 
(0.460 g, 8.61 mmol) in water (20 mL) was added and allowed to stir until all of the starting 
material had disappeared by TLC (3:1, CH2Cl2:MeOH).  Excess concentrated HCl (approx. 1 mL) 
was added until the medium was acidic, when a yellow precipitate fell out of solution.  This 
precipitate was filtered out, washed with ice cold water, and air-dried to give the product 14 
(0.855 g, 91.9 %): mp 251-254 ºC. TLC (4:1, EtOAc: MeOH) Rf = 0.35.  1H NMR data δ 12.05 
(s, 1H), 10.21 (s, 1H), 8.17 (d, J = 1.87 Hz, 1H), 8.08 (t, J = 5.62, 5.72 Hz, 1H), 7.57 ( d, J = 1.95 
Hz, 1H), 7.19 (d, J = 1.73 Hz, 1H), 6.85 (d, J = 1.79 Hz, 1H), 3.94 (s, 3H), 3.79 ( s, 3H), 3.18 ( q, 
J = 6.62, 6.09, 6.66 Hz, 2H), 2.24 (t, J = 7.42, 7.36 Hz, 2H) 1.69 (p, J = 7.10, 7.10, 7.11, 7.21 Hz, 
2H).  13C NMR data: δ 174.31, 161.19, 156.85, 133.79, 128.22, 126.31, 123.23, 121.33, 117.97, 
107.56, 104.01, 37.85, 37.50, 36.04, 31.15, 24.74. 
N-({1-methyl-4-[2-(5-methyl-3-nitrocyclopenta-1,3-dien-1-yl)prop-2-en-1-yl]-1H-
pyrrol-2-yl}carbonyl)-β-alanine (15).  Compound 15 was synthesized using a procedure similar 
to the one described above for 14 using 1.29 g (3.29 mmol) of 8 to give 15 (1.17 g, 99 %): mp 
230-234 °C. TLC (6:1, EtOAc: MeOH) Rf = 0.52.  1H NMR data: δ 12.19 (s, 1H), 10.23 (s, 1H), 
8.17 (d, J = 1.83 Hz, 1H), 8.08 (t, J = 5.52, 5.60 Hz, 1H) 7.56 (d, J = 1.98, 1H) 7.20 (d, J = 1.78 
Hz, 1H), 6.83 (d, J = 1.84, 1H), 3.94 (s, 3H), 3.80 (s, 3H), 3.35 (q, J = 7.04, 5.75, 7.13 Hz, 2H), 
2.46 (t, J = 8.31, 7.09 Hz, 2H).  13C NMR data: δ 173.01, 161.61, 156.85, 133.78, 128.24, 126.30, 
123.02, 121.36, 118.08, 107.57, 104.10, 37.50, 36.07, 34.88, 34.02. 
2-Deoxy-2-(4-methoxybenzylidene)amino-β-D-glucopyranose (16).  Compounds 16 
was synthesized from D-glucosamine hydrochloride as described in literature.26  Sodium 
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hydroxide (11 g) was dissolved in 235 mL of water in a 500 mL round bottom flask  that was 
cooled to 0 ºC and D-glucosamine hydrochloride (50.01 g, 0.232 mol) was added.  The solution 
was stirred until clear (5 min.) and 4-methoxybenzaldehyde (31.0 mL, 0.264 mol) was added and 
stirred at 0 ºC for 30 min. and then left unstirred at 0 ºC for 48 hours.  A white precipitate fell out 
of solution and was filtered under vacuum and dried to give 16 (59.76 g, 75.2 %): mp 154-155ºC.  
1H NMR data: δ 8.11 (s, 1H), 7.67 (d, J = 8.66 Hz, 2H) 6.97 (d, J = 8.68 Hz, 2H), 6.52 (d, J = 
5.67 Hz, 1H), 4.93 (d, J = 5.18 Hz, 1H), 4.82 (d, J = 5.55 Hz, 1H), 4.69 (t, J = 6.50, 6.49 Hz, 1H), 
4.55 (t, J = 5.79, 5.72 Hz, 1H), 3.78 (s, 3H), 3.72(dd, J = 5.40, 4.70, 5.39 Hz, 1H), 3.45 (m, 2H), 
3.23 (m, 1H), 3.15 (m, 1H), 2.78 (t, J = 8.35, 8.60 Hz, 1H).  13C NMR data: δ 161.25, 161.06, 
129.64 (2C), 129.11, 113.91 (2C), 95.64, 78.19, 76.86, 74.60, 70.37, 61.27, 55.29. 
 1,3,4,6-Tetra-O-acetyl-2-deoxy-2-(4-methoxybenzylidene)amino- β-D-glucopyranose 
(17).  Compound 17 was synthesized as described in literature.26 The imine 16 (55.01 g, 0.161 
mol) was dissolved in anhydrous pyridine (350 mL) at 0 ºC in a 1 L round bottom flask.  Acetic 
anhydride (200 mL) was then added to the solution and stirred while allowing the solution to 
warm to room temperature overnight.  This mixture was concentrated to half the original volume 
on a rotary evaporator maintaining the temperature below 30 °C and was then poured into ice 
water (~1 L) and stirred for 1 h.  The white precipitate that was formed was filtered under 
vacuum to give 17 (62.52 g, 78.6%): mp 172-173ºC.  1H NMR data: δ 8.27 (s, 1H), 7.64 (d, J = 
8.77 Hz, 2H), 6.97 (d, J = 8.76 Hz, 2H), 6.06 (d, J = 8.24 Hz, 1H), 5.44 (t, J = 9.67, 9.68 Hz, 1H), 
4.97 (t, J = 9.61, 9.65 Hz, 1H), 4.26 (m, 2H), 4.01 (d, J = 10.60 Hz, 1H), 3.78 (s, 3H), 3.44 (t, J = 
8.48, 9.52 Hz, 1H), 2.00 (s, 3H), 1.97 (s, 6H), 1.81 (s, 3H).  13C NMR data: δ 170.04, 169.44, 
168.98, 168.59, 164.45, 161.83, 129.93 (2C), 128.27, 114.19 (2C), 92.54, 72.35, 72.26, 71.54, 
67.82, 61.66, 55.53, 20.52, 20.43 (2C), 20.18. 
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 1,3,4,6-Tetra-O-acetyl-2-amino-2-deoxy-β-D-glucopyranose  hydrochloride (18).  
Compound 18 was synthesized as described in literature.26 Acetyl chloride (0.156 mL) was 
added to anhydrous methanol (1.08 mL) with constant stirring at 0 ºC in a 100 mL round bottom 
flask.  This mixture was then added to a stirred solution of the imine 17 (1.00 g, 0.002 mol) in 
acetone (30.4 mL) at room temperature.  This mixture was stirred for 45 min. and then cooled to 
0 ºC.  Ether (10.8 mL) was then added to the cooled solution and stirred for an additional 45 min. 
at 0 °C.  Vacuum filtration of the white precipitate gave 18 (0.665 g, 81%): mp: 120 °C-
decomposition. 1H NMR data: δ 8.83 (s, 3H), 5.90 (d, J = 8.64 Hz, 1H), 5.35 (t, J = 10.09, 9.48 
Hz, 1H), 4.92 (t, J = 9.82, 9.36 Hz, 1H), 4.17 (dd, J = 4.33, 8.12, 4.29 Hz, 1H), 4.01 (m, 2H), 
3.55 (t, J= 9.85, 9.15 Hz, 1H), 2.16 (s, 3H), 2.02 (s, 3H), 1.98 (s, 3H), 1.96 (s, 3H).  13C NMR 
data: δ 169.98, 169.78, 169.32, 168.65, 90.10, 71.60, 70.33, 67.79, 61.26, 52.12, 20.96, 20.87, 
20.51, 20.36. 
 1,3,4,6-tetra-O-acetyl-2-deoxy-2-[(4-{[(1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-
yl)carbonyl]amino}-1H-pyrrol-2-yl)carbonyl]amino}butanoyl)amino] hexopyranose (19).  
In a flask flushed with Ar, 18 (3.23 g, 8.4 mmol) was dissolved in 70 mL anhydrous DMF along 
with EDCI (2.49 g, 1.5 eq.), DMAP (2.57 g, 2.5 eq.), HOBT (3.86 g, 3 eq.), and CuCl2 (0.113 g, 
0.1 eq.).  Once in solution, the carboxylic acid 14 (3.16 g, 8.4 mmol) was then added and the 
solution was allowed to stir at room temperature over two days until disappearance of starting 
material as indicated by TLC (3:1, EtOAc: MeOH).  The solution was diluted with 100 mL DCM 
and the organic solutions was extracted with H2O (2x, 100 mL), saturated NaHCO3 (2x, 150 mL), 
and 1M HCl (2x, 150 mL).  The organic layer was dried over MgSO4.  The resulting solution 
was rotary evaporated until a solid began to fall out of solution.  The solution was then warmed 
up again until the solid redissolved and was then cooled slowly in the freezer when yellow solid 
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crystals fell out of solution, which were filtered and dried to give the product 19 (5.35 g, 90.1 %): 
mp 174-177 °C. TLC (6:1, CHCl3: MeOH) Rf = 0.51.  1H NMR data: δ 10.23 (s, 1H), 8.17 (s, 
1H), 8.05 (m, 2H), 7.56 (d, J = 1.70 Hz,1H), 7.19 (s, 1H), 6.84 (s, 1H), 5.70 (d, J = 8.83 Hz, 1H), 
5.16 (t, J = 9.90, 10.05 Hz, 1H), 4.88 (t, J = 9.83, 9.71 Hz, 1H), 4.18 (m, 1H), 3.99 (m, 3H), 3.94 
(s, 3H), 3.78 (s, 3H), 3.09 (m, 2H), 2.06 (s, 3H), 2.03 (s, 3H), 1.98 (s, 3H), 1.91 (s, 3H), 1.64 (m, 
2H).  13C NMR data: δ  172.27, 170.06, 169.62, 169.29, 168.92, 161.13, 156.86, 133.78, 128.23, 
126.30, 123.19, 121.32, 118.00, 107.56, 104.00, 91.73, 72.17, 71.52 , 68.06, 61.48, 51.80, 37.97, 
37.49, 36.04, 33.26, 25.68, 20.51 (2C), 20.41, 20.32. 
 1,3,4,6-tetra-O-acetyl-2-deoxy-2-[(3-{[(1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-
yl)carbonyl]amino}-1H-pyrrol-2-yl)carbonyl]amino}propanoyl)amino] hexopyranose (20).  
Compound 20 was synthesized using a procedure similar to the one described above for 19 using 
1.00 g (2.75 mmol) of 15 and 1.05 g (2.75 mmol) of 18 to give 20 (1.57 g, 82 %): mp 169-173 ° 
C. TLC (6:1, CHCl3:MeOH) Rf = 0.53.  1H NMR data: δ 10.27 (s, 1H), 8.19 (d, J = 1.78 Hz, 1H), 
8.12 (d, J = 9.17 Hz, 1H), 8.05 (t, J = 5.52, 5.67 Hz, 1H), 7.59 (d, J = 1.87 Hz, 1H), 7.22 (d, J = 
1.68 Hz, 1H), 6.82 (d, J = 1.75, 1H), 5.72 (d, J = 8.84 Hz, 1H), 5.18 (t, J = 9.65, 10.26 Hz, 1H), 
4.89 (t, J = 9.77, 9.71 Hz, 1H), 4.19 (dd, J = 4.42, 8.04, 4.28 Hz, 1H), 3.98 (m, 3H), 3.95 (s, 3H), 
3.80 (s, 3H), 3.30 (q, J = 6.40, 6.95 Hz, 2H), 2.31 (t, J = 7.45, 7.19 Hz, 2H), 2.01 (s, 3H), 2.00 (s, 
3H), 1.97 (s, 3H), 1.88 (s, 3H).  13C NMR data: δ 170.80, 170.05, 169.61, 169.28, 168.88, 161.14, 
156.86, 133.77, 128.24, 126.29, 122.99, 121.38, 118.13, 107.63, 103.99, 91.68, 72.16, 71.51, 
68.02, 61.49, 51.87, 37.50, 36.05, 35.55, 35.39, 20.52 (2C), 20.42, 20.25. 
 1,3,4,6-tetra-O-acetyl-2-{[4-({[4-({[4-(acryloylamino)-1-methyl-1H-pyrrol-2-
yl]carbonyl}amino)-1-methyl-1H-pyrrol-2-yl]carbonyl}amino)butanoyl]amino}-2-
deoxyhexopyranose (21).  Compound 19 (1.00 g, 1.425 mmol) was dissolved in 100 mL EtOH 
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and 500 mg Pd/C was added in a parr jar.  The mixture was shaken under pressurized hydrogen 
(75 psi) until 19 had disappeared as indicated by TLC (3:1, EtOAc:MeOH).  The Pd/C was 
filtered out through celite, and the solution was concentrated by rotary evaporation and the 
residue was kept under vacuum overnight.  The flask with the residue was flushed with Ar, and 
the residue was dissolved in anhydrous THF (30 mL) and anhydrous DIEA (0.869 mL) was 
added to the solution.  The solution was bubbled with Ar and cooled to -40 °C.  Acryloyl 
chloride (0.116 mL) was added dropwise to the solution which was then allowed to stir below -
20 °C, protected from light, until the reaction was complete as indicated by TLC (6:1, 
CHCl3:MeOH).  The solution was concentrated by rotary evaporation and was dissolved in 30 
mL DCM and extracted with 20 mL H20.  The DCM layer was crystallized to give pure 21 
(0.3845 g, 37 %): mp 130-135 °C.  TLC (6:1, CHCl3:MeOH) Rf = 0.48.  1H NMR data: δ  10.09 
(s, 1H), 9.88 (s, 1H), 8.01 (m, 2H), 7.25 (d, J = 1.78 Hz, 1H), 7.17 (d, J = 1.77 Hz, 1H), 6.90 (d, J 
= 1.83 Hz, 1H), 6.84 (d, J = 1.80 Hz, 1H), 6.36 (m, 1H), 6.17 (m, 1H), 5.70 (d, J = 8.85 Hz, 1H), 
5.64 (dd, J = 2.80, 7.94, 2.22 Hz, 1H), 5.16 (t, J = 10.35, 9.60 Hz, 1H), 4.88 (t, J = 9.52, 9.70 Hz, 
1H), 4.17 (dd, J = 4.75, 8.08, 4.20 Hz, 1H), 4.00 (m, 4H), 3.83 (s, 3H), 3.78 (s, 3H), 3.10 (q, J = 
6.65, 6.68, 6.32 Hz, 2H), 2.04 (s, 3H), 2.00 (s, 3H), 1.96 (s, 3H), 1.91 (s, 3H), 1.64 (p, J = 7.32, 
7.20, 7.08, 7.37 Hz, 2H).  13C NMR data: δ  172.23, 170.05, 169.61, 169.28, 168.91, 161.65, 
161.24, 158.30, 131.50, 125.62, 123.03, 122.90, 121.99, 121.69, 118.44, 117.87, 104.16, 103.98, 
91.74, 72.18, 71.52, 68.06, 61.48, 51.80, 37.94, 36.19, 35.96, 33.27, 25.72, 20.42 (3C), 20.33. 
 1,3,4,6-tetra-O-acetyl-2-{[3-({[4-({[4-(acryloylamino)-1-methyl-1H-pyrrol-2-
yl]carbonyl}amino)-1-methyl-1H-pyrrol-2-yl] carbonyl}amino)propanoyl]amino}-2-
deoxyhexopyranose (22).  Compound 22 was synthesized using a procedure similar to the one 
described above for 21 using 0.500 g (0.723 mmol) of 20 and 59 µL (0.723 mmol) of acryloyl 
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chloride to give 22 (0.327 g, 63 %): mp 137-137 ° C. TLC (6:1, CHCl3:MeOH) Rf = 0.30.  1H 
NMR data: δ 10.11 (s, 1H), 9.90 (s, 1H), 8.09 (d, J = 9.16 Hz, 1H), 7.97 (t, J = 5.28, 5.69 Hz, 
1H), 7.26 (d, J = 1.59 Hz, 1H), 7.19 (d, J = 1.61, 1H), 6.90 (d, J = 1.72 Hz, 1H), 6.80 (d, J = 1.67 
Hz, 1H), 6.35 (m, 1H), 6.17 (dd, J =  1.99, 14.91, 2.15 Hz, 1H), 5.71 (d, J = 8.84 Hz, 1H) 5.66 
(dd, J = 1.98, 8.02, 2.16 Hz, 1H), 5.17 (t, J = 9.73, 10.19 Hz, 1H), 4.88 (t, J = 9.80, 9.76 Hz, 1H), 
4.18 (dd, J = 4.63, 8.07, 4.30 Hz, 1H), 3.97 (m, 3H), 3.83 (s, 3H), 3.78 (s, 3H), 3.29 (m, 2H), 
2.29 (t, J = 7.47, 7.25 Hz, 2H), 1.99 (s, 3H), 1.98 (s, 3H), 1.96 (s, 3H), 1.87 (s, 3H).  13C NMR 
data: δ  170.81, 170.05, 169.62, 169.29, 168.89, 161.64, 161.23, 158.29, 131.49, 125.62, 123.01, 
122.70, 122.03, 121.68, 118.44, 118.00, 104.10, 103.99, 91.68, 72.16, 71.51, 68.01, 61.48, 51.85, 
41.34, 36.19, 35.97, 35.58, 35.37, 20.52, 20.42 (2C), 20.25. 
 Ethyl 4-({[4-({[4-(acryloylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl}amino)-1-
methyl-1H-pyrrol-2-yl]carbonyl}amino)butanoate (23).  The NO2PyPyγOEt 7 (1.45 g, 3.58 
mmol) was dissolved in ethanol (200 mL) and Pd/C (500 mg) was added in a parr jar.  The 
mixture was shaken under pressurized hydrogen (75 psi) until 7 had disappeared as indicated by 
TLC (EtOAc).  The Pd/C was filtered out through celite, and the solution was rotary evaporated 
down to afford the amine which was kept under vacuum overnight.  The amine flushed with Ar 
was dissolved in anhydrous THF (44 mL) and anhydrous DIEA (2.07 mL) was added to the 
solution.  The solution was bubbled with Ar and cooled to -40 °C.  Acryloyl chloride (0.292 mL) 
was added dropwise to the solution and allowed to stir below -20 °C protected from light until 
the reaction was complete as indicated by TLC (6:1, CHCl3:MeOH).  The solution was 
concentrated by rotary evaporation dissolved in 30 mL EtOAc and extracted with 30 mL H20.  
The EtOAc layer was dried over MgSO4 and concentrated by rotary evaporation to give pure 23 
(1.40 g, 91 %): mp 70-75 °C.  TLC (EtOAc) Rf = 0.29.  1H NMR data: δ  10.09 (s, 1H), 9.89 (s, 
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1H), 8.03 (t, J = 5.46, 5.59 Hz,1H), 7.26 (d, J = 1.41 Hz, 1H), 7.17 (d, J = 1.32 Hz, 1H), 6.90 (d, 
J = 1.52 Hz, 1H), 6.85 (d, 1.45 Hz, 1H), 6.36 (m, 1H), 6.19 (dd, J = 1.90, 15.04, 1.99 Hz, 1H), 
5.65 (dd, J = 1.87, 2.02 Hz, 1H), 4.03 (q, J = 7.11, 7.11, 7.13 Hz, 2H), 3.83 (s, 3H), 3.78 (s, 3H), 
3.17 (q, J = 6.49, 6.11, 6.47 Hz, 2H), 2.29 (t, J = 7.80, 7.49 Hz, 2H), 1.72 (p, J = 6.97, 7.08, 7.06, 
7.04 Hz, 2H), 1.16 (t, J = 7.10, 7.10 Hz, 3H).  13C NMR data: δ 172.73, 161.64, 161.30, 158.29, 
131.51, 125.59, 123.04, 122.89, 122.00, 121.70, 118.44, 117.87, 104.18, 103.96, 59.76, 37.71, 
36.20, 35.96, 31.06, 24.72, 14.13. 
 1,3,4,6-tetra-O-acetyl-2-deoxy-2-({4-[({1-methyl-4-[({1-methyl-4-[(3-
sulfopropanoyl)amino]-1H-pyrrol-2-yl}carbonyl)amino]-1H-pyrrol-2-
yl}carbonyl)amino]butanoyl}amino)hexopyranose (25).  The alkene 21 (1.00 g, 1.37 mmol), 
was dissolved in THF (20 mL) and H2O (80 mL) was added.  To the solution, 45 % NH4HSO3 (6 
mL) and 50 % H2O2 (0.5 mL) were added and the solution was allowed to reflux for 16 hours at 
which time TLC (6:1, CHCl3, MeOH) indicated the complete disappearance of 21 and the 
formation of a baseline spot.  The solution was concentrated by rotary evaporation and the solid 
was washed with MeOH, which gave a yellow solution leaving behind a white salt.  The yellow 
solution was concentrated by rotary evaporation to give a yellow solid that was dissolved in a 
minimal amount of H2O.  The solution was acidified to a pH of approximately 1 with 
concentrated H2SO4 and the aqueous solution was evaporated off.  Flash column 
chromatography (1:1:1, EtOAc:DCM:MeOH) was used to purify the resulting solid to give 
slightly impure 25 (294 mg, 26.5 %): mp  decomposition 170 °C.  TLC (1:1:1, 
EtOAc:DCM:MeOH) Rf = 0.57.  1H NMR data: δ  10.02 (s, 1H), 9.91 (s, 1H), 8.09 (m, 2H), 7.11 
(s, 1H), 7.09 (s, 1H), 6.80 (s, 2H), 5.20 (m, 1H), 5.00 (m, 1H), 4.85 (m, 1H), 4.15 (m, 2H), 4.00 
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(m, 2H), 3.82 (s, 3H), 3.78 (s, 3H), 3.12 (m, 2H), 2.68 (m, 2H), 2.57 (m, 2H), 2.15 (m, 2H), 1.75 
(m, 2H). 
 2-deoxy-2-[(4-{[(1-methyl-4- {[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl] amino}-
1H-pyrrol-2-yl)carbonyl]amino}butanoyl)amino]hexopyranose (26).  Compound 19 (10 mg) 
was dissolved in 7 N NH3 in MeOH and allowed to stir at room temperature until 19 had 
disappeared as indicated by TLC (6:1, CHCl3:MeOH).  The solution was concentrated by rotary 
evaporation to give 26.  1H NMR data: δ  10.23 (s, 1H), 8.17 (d, J = 2.0 Hz, 1H), 8.09 (s, 1H), 
7.63 (m, 1H), 7.57 (d, J = 2.0 Hz, 1H), 7.20 (d, J = 2.0 Hz, 1H), 6.85 (d, J = 2.0 Hz, 1H), 4.91 (m, 
2H), 4.41 (m, 1H), 3.94 (s, 3H), 3.80 (s, 3H), 3.58 (m, 2H), 3.16 (m, 2H), 2.15 (m, 2H), 1.75 (m, 
2H). 
   2-[(5-{[(5-{[(4-ethoxy-4-oxobutyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-
yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]-2-oxoethanesulfonic acid (27).  To a 
solution of alkene ester 23 (1.4 g, 3.26 mmol) in 65 mL of 4:1 EtOH: H2O, NaHSO3 (678 mg, 
6.52 mmol) in 10 mL of H2O was added.  The pH was adjusted to about 8 with 5 % NaOH and 
the mixture was refluxed until 23 had disappeared and a spot appeared on the baseline by TLC 
(6:1 CHCl3: MeOH).  The solution was cooled in an ice bath and concentrated HCl was added 
until the pH was about 1.  The solvents were removed by rotary evaporation and the residue was 
dried under vacuum.  The residue was then stirred in EtOH and the insoluble white salt was 
filtered off.  This yellow solution was then concentrated by rotary evaporatin and dried to afford 
the sulfonic acid ester 27 (1.48 g, 89 %): TLC (1:1:1 EtOAc:DCM:MeOH) Rf = 0.57.  1H NMR 
data: δ 9.96 (s, 1H), 9.85 (s, 1H), 8.03 (t, 1H), 7.16 (d, 1H), 7.14 (d, 1H), 6.84 (s, 2H), 4.03 (q, 
2H), 3.80 (s, 3H), 3.77 (s, 3H), 3.16 (m, 2H), 2.66 (m, 2H), 2.54 (m, 2H), 2.30 (t, 2H), 1.70 (q, 
2H), 1.16 (t, 3H).    
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 4-[({1-methyl-4-[({1-methyl-4-[(sulfoacetyl)amino]-1H-pyrrol-2l}carbonyl) amino]-
1H-pyrrol-2-yl}carbonyl)amino]butanoic acid (29).  The sulfonic acid ester 27 (1.48 g, 3.26 
mmol) was dissolved in EtOH (60 mL) and NaOH (832 mg) dissolved in H2O (50 mL) was 
added.  This solution was allowed to stir until the disappearance of 27 indicated by TLC (1:1, 
EtOAc:MeOH).  The solution was then cooled in an ice bath and concentrated HCl was added 
until acidic (pH approximately 1).  The solution was concentrated by rotary evaporation to give a 
white and yellow solid, which was sitrred with EtOH which resulted in a yellow solution and an 
insoluble white solid.  The solid was filtered off and the yellow solution was rotary evaporated 
down to give pure 29 (1.31 g, 81 %): mp 184-188 °C.  TLC (1:1:1 EtOAc:DCM:MeOH) Rf = 
0.55.  1H NMR data: δ 9.97 (s, 1H), 9.85 (s, 1H), 8.03 (t, 1H), 7.16 (d, 1H), 7.14 (d, 1H), 6.84 (s, 
2H), 3.80 (s, 3H), 3.77 (s, 3H), 3.18 (m, 2H), 2.67 (m, 2H), 2.54 (m, 2H), 2.23 (t, 2H), 1.69 (q, 
2H).  13C NMR data: δ 174.37, 168.32, 161.37, 158.43, 122.94, 122.72, 122.11, 122.09, 118.21, 
117.88, 104.27, 103.98, 59.82, 47.55, 36.16, 36.00, 32.23, 31.23, 24.81. 
 [1-methyl-4-[1-methyl-4-(2-propenamido)-imidazole-2-carboxamido]pyrrole-2-
carboxamido]propane (31).  Compound 31 was previously made in the laboratory following 
procedures described in literature.10 
 [1-methyl-4-[1-methyl-4-(3-sulfopropanamido)imidazole-2-carboxamido]-pyrrole-2-
carboxamido]propane (32).  To a solution of alkene 31 (0.500 g, 1.4 mmol) in 50 mL of 4:1 
EtOH: H2O, NaHSO3 (291 mg, 2.8 mmol) in 5 mL of H2O was added.  The pH was adjusted to 
about 8 with 5 % NaOH and the mixture was refluxed until 31 had disappeared and a spot 
appeared on the baseline on TLC (EtOAc).  The solution was cooled in an ice bath and 
concentrated HCl was added until the pH was about 1 and the solution was cooled in the freezer 
for 2 h.  A yellow precipitate fell out of solution which was filtered out to give 32 (0.364 g, 59 
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%): mp 264-268 °C.  TLC (1:1:1 EtOAc:DCM:MeOH) Rf = 0.55.  1H NMR data: δ 10.35 (s, 1H), 
10.00 (s, 1H), 8.00 (s, 2H), 7.41 (d, J = 0.71 Hz, 1H), 7.20 (s, 1H), 6.93 (s, 1H), 3.92 (s, 3H), 
3.78 (s, 3H), 3.10 (d, J = 5.03 Hz, 2H), 2.68 (m, 2H), 2.62 (m, 2H), 1.47 (sextet, J = 7.28, 7.06, 
7.34, 7.23, 6.85 Hz, 2H), 0.85 (t, J = 7.37, 6.59 Hz, 3H).  13C NMR data: δ 169.11, 161.15, 
155.18, 135.37, 133.77, 123.45, 121.05, 118.01, 113.97, 104.20, 47.10, 36.08, 35.13, 31.77, 
22.64, 11.51.   
 [1-methyl-4-[1-methyl-4-(3-(methoxysulfonyl)-propanamido)imidazole-2-
carboxamido]pyrrole-2-carboxamido]propane (33).  Compound 32 (0.136 g, 0.309 mmol) 
was suspended in anhydrous dioxane (22 mL) and warmed to 55 °C in an oil bath.  To the 
suspension, 3-methyl-p-tolyltriazine (100 mg, 2.2 eq) was added and the mixture was allowed to 
stir for 5 h when a new spot appeared on TLC (EtOAc).  The product was purified by flash 
column chromatography (EtOAc) to give 33 (79.2 mg, 56.6 %) which was stored under Ar in the 
freezer to prevent hydrolysis:  1H NMR data: δ 10.48 (s, 1H), 9.94 (s, 1H), 8.03 (t, J = 5.70, 5.37 
Hz, 1H), 7.41 (s, 1H), 7.26 (s, 1H), 6.89 (s, 1H), 3.92 (s, 3H), 3.85 (s, 3H), 3.78 (s, 3H), 3.66 (t, J 
= 12.41, 12.73 Hz, 2H), 3.12 (q, J = 6.77, 6.37, 6.16 Hz, 2H), 2.83 (t, J = 13.16, 14.38 Hz, 2H), 
1.47 (sextet, J = 7.32, 7.36, 7.21, 7.24, 7.20 Hz, 2H), 0.85 (t, J = 7.42, 7.30 Hz, 3H).  
 Methyl 1-methyl-4-{[(1-methyl-4-{[(2-oxo-2H-chromen-3-yl)carbonyl] amino}-1H-
pyrrol-2-yl)carbonyl]amino}-1H-pyrrole-2-carboxylate (34).  This compound was made 
previously in lab using procedures similar to forming 36.  
 1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-N-propyl-1H-
pyrrole-2-carboxamide (35).  To a solution of propylamine (0.281 mL, 3.42 mmol), EDCI 
(1.01 g, 1.5 eq), DMAP (1.04 g, 2.5 eq), HOBt (1.57 g, 3 eq), and CuCl2 (46 mg, 0.1 eq) in dry 
DMF (30 mL), the carboxylic acid (13) (1.0 g, 3.42 mmol) was added.  The solution was allowed 
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to stir under Ar until 13 had disappeared as indicated by TLC (EtOAc).  The solution was diluted 
with 60 mL EtOAc and washed with H2O (2x, 60 mL), saturated NaHCO3 (2x, 115 mL), and 1M 
HCl (2x, 115 mL).  The organic layer was dried over MgSO4 and the resulting yellow solution 
was concentrated by rotary evaporation to give pure 35 (0.627 g, 55%): mp 222-226 °C.  TLC 
(EtOAc) Rf = 0.43.  1H NMR data: δ 10.22 (s, 1H), 8.17 (d, J = 1.85 Hz, 1H), 8.05 (t, J = 5.69, 
5.68 Hz, 1H), 7.57 (d, J = 1.99 Hz, 1H), 7.19 (d, J = 1.78 Hz, 1H), 6.83 (d, J = 1.86 Hz, 1H), 3.94 
(s, 3H), 3.79 (s, 3H), 3.11 (q, J = 6.48, 6.97, 6.43 Hz, 2H), 1.47 (sextet, J = 7.40, 7.34, 7.08, 7.22, 
7.33 Hz, 2H), 0.85 (t, J = 7.36, 7.44 Hz, 3H).    13C NMR data: δ 161.11, 156.85, 133.79, 128.24, 
126.32, 123.37, 121.30, 117.87, 107.56, 103.92, 37.50, 36.03, 22.60, 11.46. 
 1-methyl-4-{[(1-methyl-4-{[1-(2-oxo-2H-chromen-3-yl)vinyl]amino}-1H-pyrrol-2-
yl)carbonyl]amino}-N-propyl-1H-pyrrole-2-carboxamide (36).  The NO2PyPyNHPr 35 
(0.200 g, 0.60 mmol) was dissolved in ethanol (20 mL) and Pd/C (160 mg) was added in a parr 
jar.  The mixture was shaken under pressurized hydrogen (75 psi) until 35 had disappeared as 
indicated by TLC (EtOAc).  The Pd/C was filtered out through celite, and the solution was 
concentrated by rotary evaporation to afford a residue which was kept under vacuum overnight.  
The residue in the flask was dissolved in dry DMF (10 mL) and EDCI (178 mg, 1.5 eq), DMAP 
(147 mg, 2 eq), HOBt (276 mg, 3 eq), and CuCl2 (8 mg, 0.1 eq) were added.  To this solution 
coumarin-3-carboxylic acid (114 mg, 0.6 mmol) was added and allowed to stir until the 
coumarin-3-carboxylic acid as indicated by TLC (EtOAc).  The solution was diluted with 20 mL 
EtOAc and the organic solution was extracted with H20 (2x, 20 mL), saturated NaHCO3 (2x, 40 
mL), and 10 % HCl (2x, 40 mL).  The organic layer was dried over MgSO4 and the solution was 
cooled in the freezer to crystallize the product and the crystals were filtered out to afford the pure 
yellow 36 (120 mg, 42 %): mp 200-202 °C. TLC (EtOAc) Rf = 0.45.  1H NMR data: δ 10.52 (s, 
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1H), 9.86 (s, 1H), 8.89 (s, 1H), 8.01 (m, 2H), 7.76 (td, J = 1.57, 7.09, 1.16, 5.87, 1.6 Hz, 1H), 
7.53 (d, J = 8.31 Hz, 1H), 7.48 (t, J = 6.89, 7.3 Hz, 1H), 7.41 (d, J = 1.78 Hz, 1H), 7.17 (d, J = 
1.77 Hz, 1H), 7.09 (d, J = 1.84 Hz, 1H), 6.84 (d, J = 1.85 Hz, 1H), 3.87 (s, 3H), 3.79 (s, 3H), 
3.11 (q, J = 6.48, 6.98, 5.98 Hz, 2H), 1.48 (sextet, J = 7.40, 7.33, 7.10, 7.21, 7.29 Hz, 2H), 0.86 (t, 
J = 7.34, 7.46 Hz, 3H).  13C NMR data: δ 161.21, 160.75, 158.14, 158.09, 153.83, 147.00, 134.15, 
130.27, 125.29, 123.29, 123.16, 121.93, 120.78, 119.45, 118.91, 118.60, 117.68, 116.25, 104.37, 
104.01, 36.30, 35.95, 22.62, 11.47. 
 Methyl 4-{[(4-acetyl-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1-methyl-1H-
pyrrole-2-carboxylate (37).  The nitro compound 9 (0.50 g, 1.63 mmol) was dissolved in 60 mL 
EtOH and Pd/C (0.40 g) was added in a parr jar.  The mixture was shaken under pressurized 
hydrogen (75 psi) until 9 had disappeared as indicated by TLC (EtOAc).  The Pd/C was filtered 
out through celite, and the solution was rotary evaporated down to afford a residue which was 
kept under vacuum overnight.  The residue in the flask was dissolved in dry THF (15 mL) under 
Ar and DIEA was added to the solution (0.568 mL).  The solution was cooled to -30 °C and Ar 
was bubbled through the solution for 10 minutes.  Acetyl chloride (0.116 mL) was added drop 
wise to the solution and was allowed to stir as it warmed to room temperature until the residue 
spot had disappeared as indicated by TLC (EtOAc).  The solution was concentrated by rotary 
evaporation and the solid was dissolved in 15 mL EtOAc.  This was extracted with H2O (2x, 15 
mL) and 10 % HCl (2x, 15 mL) and the organic layer was dried over MgSO4.  The organic layer 
was concentrated by rotary evaporation and cooled in the freezer overnight to allow the product 
to fall out of solution, which was filtered to afford pure 37 (0.300 mg, 58 %): mp 182-183 °C. 
TLC (EtOAc) Rf = 0.22.  1H NMR data: δ 9.88 (s, 1H), 9.82 (s, 1H), 7.44 (d, J = 1.78 Hz, 1H), 
7.13 (d, J = 1.63 Hz, 1H), 6.88 (d, J = 1.87 Hz, 1H), 6.83 (d, J = 1.72 Hz, 1H), 3.82 (s, 3H), 3.80 
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(s, 3H), 3.72 (s, 3H), 1.96 (s, 3H).  13C NMR data: δ 166.49, 160.81, 158.40, 122.90, 122.47, 
122.19, 120.77, 118.51,  118.17, 108.36, 103.88, 50.97, 36.18, 36.09, 23.08. 
 4-{[(4-acetyl-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1-methyl-1H-pyrrole-2-
carboxylic acid (38).  Compound 37 (0.185 g, 0.581 mmol) was dissolved in EtOH (10 mL) and 
NaOH (0.93 g) in H2O (7.5 mL) was added to the solution.  The solution was allowed to reflux 
until 37 had disappeared as indicated by TLC (EtOAc) in about 3 hr.  The solution was 
concentrated by rotary evaporation and the aqueous solution was cooled in an ice bath.  Cold 
concentrated HCl was added until the pH was about 1 when a yellow precipitate fell out.  The 
precipitate was filtered to give pure 38 (0.177 g, 100 %): mp 135-138 °C.  TLC (4:1, CHCl3: 
MeOH) Rf = 0.31.  1H NMR data: δ 12.14 (s, 1H), 9.85 (s, 1H), 9.82 (s, 1H), 7.40 (d, J = 1.9 Hz, 
1H), 7.13 (d, J = 1.75 Hz, 1H), 6.82 (m, 2H), 3.80 (s, 6H), 1.96 (s, 3H).  13C NMR data: δ 166.50, 
161.97, 158.36, 122.60, 122.53, 122.16, 120.30, 119.49, 118.12, 108.37, 103.83, 36.15, 36.10, 
23.08. 
 Ethyl 4-{[(4-{[(4-acetyl-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1-methyl-1H-
pyrrol-2-yl)carbonyl]amino}butanoate (39).  Compound 39 was synthesized using a procedure 
similar to the one described above for 37 using 0.500 g (1.23 mmol) of 7 and 88 µL (1.23 mmol) 
of acetyl chloride to give 39 (0.328 g, 64 %): mp 126-128 ° C. TLC (6:1, CHCl3:MeOH) Rf = 
0.52.  1H NMR data: δ 9.85 (s, 1H), 9.83 (s, 1H), 8.02 (t, J = 5.45, 5.74 Hz), 7.16 (d, J = 1.69 Hz, 
1H), 7.13 (d, J = 1.71 Hz, 1H), 6.84 (d, J = 1.78 Hz, 1H), 6.82 (d, J = 1.77 Hz, 1H), 4.03 (q, J = 
7.15, 7.11, 7.11 Hz, 2H), 3.80 (s, 3H), 3.78 (s, 3H), 3.16 (q, J = 6.57, 5.79, 6.49 Hz, 2H), 2.31 (t, 
J = 7.44, 7.44 Hz, 2H), 1.96 (s, 3H), 1.72 (quintet, J = 7.16, 7.17, 7.14, 7.33 Hz, 2H), 1.16 (t, J = 
7.10, 7.09 Hz, 3H).  13C NMR data: δ 172.73, 166.47, 161.30, 158.36, 122.86, 122.69, 122.10, 
122.05, 118.02, 117.84, 104.20, 103.76, 59.77, 37.70, 36.12, 35.95, 31.06, 24.72, 23.07, 14.14.  
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 4-{[(4-{[(4-acetyl-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1-methyl-1H-pyrrol-2-
yl)carbonyl]amino}butanoic acid (40).  Compound 40 was synthesized using a procedure 
similar to the one described above for 38 using 0.328 g (0.787 mmol) of 39 to give 40 (0.292 g, 
93 %): mp 122-125 ° C. TLC (1:1:1, DCM:EtOAc:MeOH) Rf = 0.24.  1H NMR data: δ 12.02 (s, 
1H), 9.85 (s, 1H), 9.82 (s, 1H), 8.03 (t, J = 5.85 Hz, 1H), 7.16 (d, J = 1.73 Hz, 1H), 7.13 (d, J = 
1.74 Hz, 1H), 6.84 (d, J = 1.80 Hz, 1H), 6.82 (d, J = 1.83 Hz, 1H), 3.80 (s, 3H), 3.78 (s, 3H), 
3.16 (q, J = 6.60, 6.07, 6.62 Hz, 2H), 2.23 (t, J = 7.42, 7.38 Hz, 2H), 1.96 (s, 3H), 1.69 (quintet, J 
= 6.93, 7.28, 7.32, 7.29 Hz, 2H).  13C NMR data: δ 174.33, 166.49, 161.31, 158.36, 122.91, 
122.69, 122.10, 122.03, 118.02, 117.83, 104.81, 103.75, 37.83, 36.13, 35.96, 31.16, 24.76, 23.07. 
 2-oxo-N-propyl-2H-chromene-3-carboxamide (43).  Compound 43 was synthesized 
using a procedure similar to the one described above for 35 using 100 mg (0.525 mmol) of 
coumarin-3-carboxylic acid and 31 mg (0.525 mmol) of N-propylamine to give 43 (83 mg, 68.6 
%):  mp 119-121 °C.  TLC (EtOAc) Rf = 0.63.  1H NMR data: δ 8.49 (s, 1H), 8.69 (m, 1H), 7.96 
(d, J = 7.75 Hz, 1H), 7.73 (t, J = 7.35, 6.88 Hz, 1H), 7.50 (d, J = 8.32 Hz, 1H), 7.43 (t, J = 7.60, 
7.46, 1H), 3.27 (q, J = 6.90, 6.60, 6.14 Hz, 2H), 1.53 (sextet, J = 7.39, 7.37, 7.27, 7.17, 7.07 Hz, 
2H), 0.89 (t, J = 7.33, 7.46 Hz, 3H).  13C NMR data: δ  161.11, 160.51, 153.91, 147.35, 134.08, 
130.30, 125.20, 119.22, 118.57, 116.20, 40.88, 22.32, 11.44. 
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 The goal of this project was to design and synthesize compounds to produce 3-MeA 
adducts in insulin producing pancreatic β-cells.  The project involved combining an agent 
capable of causing one kind of damage on DNA (i.e. 3-MeA adduct) with a unit that can target 
this damaging agent preferentially to pancreatic β-cells.  Two different molecules were designed 
in which the cell targeting glucose unit and the DNA damaging Me-lex unit were to be linked by 
a three carbon linker or a four carbon linker shown in Figure 6.1.  A synthetic route for these 
molecules was devised comprised of 12-15 steps.  Out of the 12-15 steps of the synthesis, both of 
these molecules have been accomplished to within 2-3 steps of the final product.  Compounds 21 
and 22 shown below in Figure 6.2 have been synthesized.  
 A second goal of this project was to make these molecules in a way to introduce the 
linkers at a later stage.  Therefore, the goal was to make compound 11 shown in Figure 6.3.  
However, this route had to be modified since the ester was unable to be hydrolyzed to the 
carboxylic acid without the Michael addition at the alkene taking place.  Compound 24 was 
successfully made and there are reports that an amide can be made in the presence of a sulfonic 
acid this was verified with the test reaction described Scheme 3.23.  This process is being further 
explored in the laboratory. 
 During the course of the project it was decided to develop a binding assay to measure the 
strength of binding of the new compounds with the glucose unit attached to the target site on 
DNA because this is expected to influence the efficiency of methylation of these compounds.  A 
fluorescence assay was decided upon and two different potential fluorescent probes were 
synthesized in this project as shown in Figure 6.4.  Initial experiments have indicated that neither 
of these compounds fluoresces very strongly and  
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Figure 6.1. Structure of the final compounds to be made where R = CH2CH2CH2 or CH2CH2. 
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Figure 6.2. Structure of the compounds completed thus far. 
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Figure 6.4. Structure of 34 and 36. 
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therefore, they cannot be used directly for measurements of binding constants of the compounds 
made in this project.  The experiments indicate that the mode of connection of the coumarin to 
the dipyrroles that quenches the fluorescence and new compounds are being designed shown in 
Figure 6.5 to identify the best probe to use for these studies. 
 Once the final compounds which have the DNA-methylating unit and the cell-targeting 
unit completed these molecules can be tested with DNA for their ability to methylate DNA.  A 
measurement of these compounds obtained from the fluorescence assays can then be used to 
correlate the strength of the binding to the levels of methylation.  When the best candidates are 
identified cell targeting ability of these compounds will be investigated using cell which have the 
GLUT-2 transporter and those which do not have the GLUT-2 transporter. 
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Figure 6.5. Compounds to be made to test for fluorescence. 
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APPENDIX  
Appendix A.  Structure, number, and percent yields of the compounds. 
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Appendix B.  List of Abbreviations 
3-MeA  3-methyladenine  
3-MeG  3-methylguanine 
6-MeG  6-methylguanine 
A - adenine 
A/T  adenine-thymine 
C - cytosine 
DCM  dichloromethane 
DIEA - diisopropylethylamine 
DNA  deoxyribose nucleic acid 
DMAP - 4-Dimethylaminopyridine 
DMF  dimethylformamide 
DMSO  methyl sulfoxide 
EDCI - 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimidehydrochloride 
EtOAc  ethyl acetate 
EtOH  ethanol 
G  guanine 
HCl  hydrochloric acid 
HOBT - Hydroxybenzotriazole 
Me-lex  methyl lexitropsin 
MeOH  methanol 
NaCl  sodium chloride 
NaOH  sodium hydroxide 
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NMR  nuclear magnetic resonance 
Pd/C  palladium on carbon 
STZ  streptozotocin 
TEA  triethylamine 
THF - tetrahydrofuran 
TLC  thin layer chromatography 
T - thymine 
UV  ultra violet 
 
 
 
 
